

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 130 022 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

05.09.2001 Bulletin 2001/36

(51) Int Cl.7: **C07D 498/08**

// (C07D498/08, 317:00,
265:00),

(C07D498/08, 263:00, 241:00)

(21) Application number: 00104135.9

(22) Date of filing: 29.02.2000

(84) Designated Contracting States:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE

Designated Extension States:

AL LT LV MK RO SI

• Menchi, Gloria

50019 Sesto Fiorentino (Prov. Florence) (IT)

• Occhialato, Ernesto Giovanni

50142 Firenze (IT)

• Machetti, Fabrizio

59100 Prato (IT)

• Scarpi, Dina

50134 Firenze (IT)

(71) Applicant: Università Degli Studi di Firenze

50121 Florence (IT)

(72) Inventors:

• Guarna, Antonio

59011 Seano (Province of Prato) (IT)

(74) Representative: Gervasi, Gemma, Dr.

NOTARBARTOLO & GERVASI Srl,

Corso di Porta Vittoria, 9

20122 Milano (IT)

(54) **3-Aza-6,8-dioxabicyclo[3.2.1]octanes and analogues and combinatorial libraries containing them**

(57) The present invention relates to new highly functionalized heterobicycle derivatives of following general formula (I), prepared by a process which involves only two steps by using, as starting products, commercially available, or easily prepared, α -amino ketones and α,β -dihydroxy acids or α -amino- β -hydroxy


acids or α -hydroxy- β -amino acids or α,β -dithiol acids derivatives and to libraries containing compounds of formula I and to the generation of such combinatorial libraries composed of compounds of formula I, in individual synthesis, mixture synthesis, split and recombine synthesis and parallel synthesis either in manual or automated fashion.

EP 1 130 022 A1

Description

Field of the invention

[0001] The present invention refers to heterobicyclic derivatives of general formula (I)



wherein:

R_1 , is chosen in the group consisting of C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkinyl, cycloalkyl, aryl, heterocycle, aryl- C_{1-8} alkyl; heterocycle- C_{1-8} alkyl; $RR'N-C_{1-8}$ alkyl, $RR'N$ -aryl, RO -aryl, $R(O)C$ -aryl, $RO(O)C$ -aryl, $RR'N(O)C$ -aryl, $(P)-W-NR$ -aryl, $(P)-W-O$ -aryl, $(P)-W-C(O)O$ -aryl, $(P)-W-O(O)C$ -aryl, $(P)-W-C(O)RN$ -aryl, $(P)-W-NR(O)C$ -aryl;

R_2 , is chosen in the group consisting of H, C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkinyl, cycloalkyl, aryl, aryl- C_{1-8} alkyl; heterocycle- C_{1-8} alkyl; amino- C_{1-8} alkyl, aminoaryl, C_{1-8} alkyloxyaryl, hydroxyaryl, carboxyaryl, carboalkyloxyaryl, alkylcarbamoylaryl, -(side chain), -(side chain)- W -(P) or

R_1 and R_2 taken together are a C_{1-4} alkyl, C_{2-4} alkenyl, cycloalkyl, benzofused cycloalkyl, to form a bridge of 3, 4, 5, 6 terms;

R_3 , is chosen in the group consisting H, C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkinyl, cycloalkyl, aryl, aryl- C_{1-8} alkyl; heterocycle- C_{1-8} alkyl; $RR'NC_{1-8}$ alkyl, $RR'N$ aryl, $RO-C_{1-8}$ alkyl, $RO(O)C-C_{1-8}$ alkyl, $R(O)C-C_{1-8}$ alkyl, $RC(O)O-C_{1-8}$ alkyl, $RC(O)N(R)C_{1-8}$ alkyl RO -aryl, $RO(O)C$ -aryl, $R(O)C$ -aryl, $RC(O)O$ -aryl, $RC(O)N(R)$ aryl, $-CH$ (amino acid side-chain) CO_2R , $-CH$ (amino acid side-chain) $C(O)NR$, $-CH$ (amino acid side-chain)- $C(O)O$ - W -(P), $-CH$ (amino acid side-chain)- $C(O)N(R)$ - W -(P), $CH(CO_2R)$ -amino acid side-chain- W -(P), $CH(CONRR')$ -amino acid side-chain- W -(P), protecting group;

R_4 and R_5 , same or different, are chosen in the group consisting H, C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkinyl, cycloalkyl, aryl, heterocycle, aryl- C_{1-8} alkyl; heterocycle- C_{1-8} alkyl;

R_6 is chosen in the group consisting, H, C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkinyl, cycloalkyl, aryl, aryl- C_{1-8} alkyl, heterocycle, heterocycle- C_{1-8} alkyl; $-C(O)R$, $-C(O)OR$, $-C(O)NRR'$, CH_2OR , CH_2NRR' , $-C(O)NH-CH$ (amino acid side-chain) $C(O)OR$, $-C(O)O$ - W -(P), $-C(O)N(R)$ - W -(P), $-CH_2O$ - W -(P), $-CH_2N(R)$ - W -(P);

R and R' , same or different, are chosen in the group consisting of: H, C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkinyl, cycloalkyl, aryl, heterocycle, aryl- C_{1-8} alkyl; heterocycle- C_{1-8} alkyl; a protecting group, $-C(O)CH$ (amino acid side-chain)- NHR , $-NH-CH$ (amino acid side-chain) $COOR$, $-CH$ (amino acid side-chain) $COOR$;

P is resin, both soluble or bound to a solid support;

W is as linker;

X is O, S, when a is a double bond, or X is H and a is a single bond,

Y and Z , same or different, are O, S, SO, SO_2 , N-R, wherein R is as above defined;

the above said alkyl-, alkenyl-, alkinyl-, cycloalkyl-, aryl- and heterocycle-groups, being possibly substituted.

[0002] The application refers also to a process for the preparation of the above said compounds, to libraries containing them and to the generation of such combinatorial libraries composed of compounds of formula I, in mixture synthesis, split and recombine synthesis and parallel synthesis either in manual or automated fashion. Compounds of formula I and their libraries are useful to discover new leads for therapeutical applications.


State of the art

[0003] The process of discovering new therapeutically active compounds involves the screening of a large number of compounds, in order to develop a structure-activity relationships and select the structures which could represent a new lead for the biological target. Fast methods are necessary to prepare a large collection of compounds to submit to the screening and this, in recent years, can be achieved by preparation of combinatorial chemical libraries of well


designed chemical compounds by using immobilization techniques on soluble or insoluble resins. Heterocycles compounds, bearing different substituents, and functionalised with reactive groups suitable for anchoring on resins, are very useful for this new type of synthetic strategy (for example see US 5,925,527). Another important point for a well designed chemical library is the complete control of the configuration of the stereogenic centers and the possibility to have enantiopure compounds. All these above mentioned features can be incorporated in compounds of general formula (I) which can be obtained with only two reaction steps starting from easily prepared precursors, available also as pure enantiomers. This new type of compounds, having a rigid bicyclic structure, can be functionalised in several positions and allows the easy anchoring on resin support, thus representing a new scaffold for the generation of combinatorial libraries. Thus compounds of general formula (I) can be used for the discover of new leads for therapeutical applications.

[0004] Compounds of general formula (I) having $R_1 = H$, Y and Z = O, have been already prepared as it is described by us in JOC 1999, 64, 7347 by a process involving various steps starting from a suitable α -amino alcohol which is coupled with a tartaric acid derivative. The prepared intermediate required an oxidation of the primary alcohol function to the corresponding aldehyde and a subsequent transacetalization to arrive to compounds I having $R_1 = H$ and X, Y and Z = O. However, it can be seen that the above described process involves many steps which can have a negative effect on the final yields of the desired compounds and the application cannot be extended to compound having R_1 different from H, and Z and Y different from O. Moreover this above described process is limited because, involving also an oxidative step, is compatible only with the functions resistant to the oxidative conditions and requires the protection of the all function sensitive to oxidation.

[0005] Therefore the application refers to a new straightforward process which, in only two steps, can produce compounds I, where R_1 is different from H, by starting from α -aminoketone II



and acid derivative III,



commercially available or easily prepared by reported procedures. Moreover, this procedure, allowing the immobilization of each the precursors II or III to a soluble or insoluble resin support, is suitable for the synthesis of combinatorial chemical libraries (see for examples *J Med Chem* 1999, 42, 3743; US 5,958,792, US 5,302,589) either as separate synthesis, in mixture synthesis, split and recombine synthesis, parallel synthesis with manual or automated fashion.

Detailed description of the invention

[0006] The present invention allows to overcome the above said problems thanks to the compounds of formula (I) as above defined useful either as individual compounds or for generation of combinatorial chemical libraries either in mixture synthesis or parallel synthesis with manual or automated fashion.

[0007] Moreover the invention refers to a new advantageous process for the preparation of the above defined compounds of formula (I) and their use for discovering new leads for therapeutical applications.

[0008] According to the present invention in the compounds of formula (I) as above defined:

Resin (P) means any polymeric material either soluble in the solvents commonly used in organic synthesis or

bound to the solid support;

Solid support is any solid material (at room temperature) to which starting resin materials (reactive groups) may be bound;

W is any molecule which can be used as linker to bound the resin P to the reagents and the products of formula (I);

Protecting group means any group capable of preventing the atom to which it is attached from participating in an undesired reaction or bonding, as commonly used in synthesis reactions.

Amino acid side-chain means the side chain moieties of the natural occurring L or D amino acids or the non naturally occurring amino acids;

[0009] More preferably the resin is a polymeric material derivatised with a reactive group such as, for example, a $-NH_2$ group or other electron donating group such as an hydroxyl group.

[0010] Preferred solid support materials comprise polymeric compounds such as polyethylene and polystyrene compounds and related inert polymeric compounds. The substrate may be in any shape including sheets, the inside of a cylindrical vessel, or pins but are preferably in the form of spherical beads less than 1.0 cm in diameter more preferably less than 1.0 mm in diameter. A "substrate" or solid support is a conventional solid support material used in peptide synthesis. Non-limiting examples of such substrates or supports include a variety of support resins and connectors to the support resins such as those which are photocleavable, DKP-forming linkers (DKP is diketopiperazine; see, e.g., WO90/09395 incorporated herein by reference), TFA cleavable, HF cleavable, fluoride ion cleavable, reductively cleavable and base-labile linkers.

[0011] A solid support resin comprises a plurality of solid support particles which can be split into portions for separate reactions and recombined as desired.

[0012] Preferred protecting groups are those which prevent reaction or bonding of oxygen, nitrogen, carboxylic acids, thiols, alcohols, amines and the like. Such groups and their preparation and introduction are conventional in the art and include, for example, for the reactive function OH: benzyl, *tert*-butyl; acetals, esters, trialkylsilyl ethers; for COOH group: methyl, *tert*-butyl, benzyl, allyl esters; for the NH group: *t*-Boc, Fmoc, CBz, Bn, Bz.

[0013] Amino acid side-chain means the different amino acid side-chain moieties attached to an "amino acid". The term "amino acid" includes any one of the twenty L or D natural α -amino acids having as "side chain": -H of glycine; $-CH_3$ of alanine; $-CH(CH_3)_2$ of valine; $-CH_2CH(CH_3)_2$ of leucine; $-CH(CH_3)CH_2CH_3$ of isoleucine; $-CH_2OH$ of serine; $-CH(OH)CH_3$ of threonine; $-CH_2SH$ of cysteine; $-CH_2CH_2SCH_3$ of methionine; $-CH_2$ -(phenyl) of phenylalanine; $-CH_2$ -(phenyl)-OH of tyrosine; $-CH_2$ -(indole group) of tryptophan; $-CH_2COOH$ of aspartic acid; $-CH_2C(O)(NH_2)$ of asparagine; $-CH_2CH_2COOH$ of glutamic acid; $-CH_2CH_2C(O)NH_2$ of glutamine; $-CH_2CH_2CH_2-N(H)C(NH_2)NH$ of arginine; $-CH_2$ -(imidazole) group of histidine; and $-CH_2(CH_2)_3NH_2$ of lysine, comprising the same amino acid side-chain moieties bearing suitable protecting groups (Pg). In addition, the term "amino acid" include also non naturally occurring amino acids, like norleucine (Nle), norvaline (Nva), β -alanine, L or D α -phenyl glycine and others well known in the peptide art.

[0014] In the compounds of formula (I), as above defined, groups C_{1-8} alkyl, C_{2-8} alkenyl and C_{2-8} alkynyl represent linear or branched alkyl radicals as for example: methyl, ethyl, propyl, isopropyl, butyl, pentyl, hexyl, heptyl, octyl, ethylene, propene, butene, isobutene, acetylene, propyne, butyne etc

[0015] The term cycloalkyl represents: cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norbornane, canphane, adamantane.

[0016] The term aryl specifies phenyl, biphenyl and naphthyl groups substituted with one or more, and preferably one or two moieties chosen from the groups consisting of halogen, cyano, nitro, C_{1-6} alkyl. The term heterocycle represents in particular: saturated or aromatic heterocycles containing one or more N atoms, more particularly: pyridine, imidazole, pyrrole, indole, triazoles, pyrrolidine, piperidine.

[0017] The term halogen represent fluorine, chlorine, bromine, iodine.

[0018] The terms "library", "combinatorial library", "resin-derived library" and the like are used interchangeably throughout the description to mean a series of separate individual components or mixture of the compounds I, synthesized in solution or on a solid support from one or more solid phase bound resin starting materials, and their pharmaceutically acceptable salts or esters.

[0019] The synthetic process according to the invention involves only two steps and moreover uses, as starting compounds, an α -aminoketone and a carboxylic acid derivative bearing two vicinal nucleophilic groups like OH, SH, or NHR, preferably belonging to the classes of α,β -dihydroxy acid or α -amino- β -hydroxy acid or α -hydroxy- β -amino acid or α,β -dithiol acid derivatives.

[0020] In particular, the process according to the present invention allows the preparation of the compounds of formula (I) wherein:

a = double bond, and X = O or a = single bond and X = H

Y and Z, same or different are O, S, NR wherein R is above described

R_1 = methyl, ethyl, propyl, isopropyl, *t*-butyl, benzyl, phenyl, 4-hydrophenyl, 4-methoxy-phenyl, 4-carboxy-phenyl,

4-nitro-phenyl, 4-amino-phenyl, 4-halogenphenyl, 4-trifluoromethylphenyl, 2-hydrophenyl, 2-methoxy-phenyl, 2-carboxyphenyl, 2-nitro-phenyl, 2-amino-phenyl, 2-halogen-phenyl, 2-trifluoromethylphenyl C₁₋₈alkylOC(O)phenyl, hydroxy-C₁₋₈alkylphenyl, methoxy-C₁₋₈alkylphenyl, RR'NC(O)-phenyl, RR'N-C₁₋₈alkylphenyl, biphenyl, naphthyl, tetrahydronaphthyl, decahydronaphthyl, cycloalkyl, heterocycle, (P)-W-NR-phenyl, (P)-W-O-phenyl, (P)-W-C(O)O-phenyl, (P)-W-O(O)C-phenyl, (P)-W-C(O)RN-phenyl, (P)-W-NR(O)C-phenyl, wherein (P), W, R and R' are defined as above;

R₂, which can be bound with R₁ through a C₁-C₅alkyl chain, is chosen in the group consisting of H, methyl, ethyl, propyl, isopropyl, t-butyl, phenyl, 4-hydrophenyl, 4-methoxy-phenyl, 4-carboxy-phenyl, 4-amino-phenyl, benzyl, amino acid side chain-; (P)-W-amino acid side-chain;


R₃, H, methyl, ethyl, propyl, isopropyl, t-butyl, phenyl, benzyl, cycloalkyl, aryl, arylC₁₋₈alkyl; heterocycle, heterocycleC₁₋₈alkyl-CH(amino acid side-chain)CO₂R, CH(amino acid side-chain)C(O)NR, -CH(amino acid side-chain)-C(O)O-W-(P), -CH(amino acid side-chain)-C(O)N(R)-W-(P), CH(CO₂R)-amino acid side-chain-W-(P), CH(CONRR')- amino acid side-chain-W-(P), Pg, wherein (P), (amino acid side-chain), W, R and R' are defined as above;

R₄, R₅, same or different, are chosen in the group consisting H, methyl, ethyl, propyl, isopropyl, phenyl, benzyl, heterocycle

R₆ is chosen in the group consisting, H, methyl, ethyl, propyl, isopropyl, t-butyl, phenyl, benzyl, cycloalkyl, aryl, benzyl, heterocycle, heterocycleC₁₋₈alkyl; COOH, COOR, C(O)R, CONHR CONRR', CH₂OH, CH₂OR CH₂NHR, CH₂NRR', -C(O)NH-CH(amino acid side-chain)C(O)OR, -C(O)O-W-(P), -C(O)N(R)-W-(P), -CH₂O-W-(P), -CH₂N(R)-W-(P), wherein R and R' same or different and the terms "(amino acid side-chain)", "(P)", and "W" are as above defined


[0021] Among the pharmaceutically acceptable esters and salts according to the present invention the following can be mentioned: hydrochloride, sulfate, citrate, formate, phosphate.

[0022] According to the invention the above defined compounds of formula (I) can be prepared starting from compounds of general formula II



II

wherein R₁, R₂, R₃, are as above defined and III



III

wherein R₄, R₅, R₆, Y and Z are as above defined, and R₇ R₈ represent H or suitable protecting groups, (Pg) which can be same or different, cyclic or acyclic, and which can be cleaved in acidic conditions.

[0023] The α-amino ketones II are commercially available or can be prepared as shown in the scheme 2, for example starting from an α-halogen-ketone V and a primary amine VI according to known procedures (see for example *Tetrahedron Letters* 1987, 28, 1287 and references cited therein)

[0024] The acid derivatives III are commercial available or can be prepared according know procedures.

[0025] As it can be seen from the Scheme 1 the preparation of the compounds (I) according to the invention involves, in the Step 1, the reaction of the α-amino ketone II with the acid derivative III to give the amide derivative IV in the

presence of a coupling reagent. Because Step 1 involves the formation of an amide bond, all the reagents commonly used for the peptide synthesis can be applied to this step. Preferably the reaction is performed in an aprotic polar solvent, preferably CH_2Cl_2 or DMF, at a temperature comprised between 0°C - 100°C , preferably at 25°C , for a time comprised between 1 and 24 hours, preferably in the presence of a coupling agent and activator of the carboxy group,

as PyBrop, PyBOP, HATU, HOBt, HBTU, TBTU, DCC, DIC, EDC etc. and a tertiary base as NEt_3 , DIPEA, NMM. [0026] The intermediate amide IV is then cyclized into the final compound I in the Step 2, by action of an acid, which, allows the ketalization of the functions Z and Y with the carbonyl group by also removing the protecting groups Pg, when present. Also for this step the reaction conditions (temperature and time) and the type of acid and solvent are important.

[0027] The best results were obtained using a stoichiometric or preferably catalytic amount of a strong acid, preferably sulphuric acid adsorbed on silica gel, p-toluen sulphonic acid, trifluoroacetic acid, trifluoromethanesulphonic acid and performing the reaction at a temperature comprised between 0°C - 150°C , preferably at refluxing-solvent temperature, in an organic apolar solvent (for example methylene chloride, chloroform, benzene or toluene) for a time comprised between 15 min and 24 hours, preferably 30 min - 2 hours, preferably with the simultaneous removal of a portion of the solvent and eventually in the presence of molecular sieves. In these condition the final product I is obtained having $\text{X}=\text{O}$ and a double bond. The subsequent reaction on the amide bond either with usual reducing agents, for example LiAlH_4 , $\text{BH}_3\cdot\text{THF}$, $\text{BH}_3\cdot\text{Me}_2\text{S}$ and like, produce compounds I wherein $\text{X}=\text{H}$ and a is single bond, or by the use of sulphurating agents, like the Lawesson reagent, produce compounds I wherein $\text{X}=\text{S}$ and a is double bond.

[0028] Owing to the importance to produce combinatorial chemical libraries, the above reported procedure can be modified by using one of the two components II and III of the Step 1 bound to a resin through a suitable linker. In this case, the formed compound IV is also bound to a resin, and the following step 2 can be performed either maintaining the final product I bound to the resin or with a simultaneous cleavage from the resin. Because the starting α -amino ketone II can be easily prepared from an α -halogen ketone V and a primary amine VI (as reported in the Scheme 2), this can increase the molecular diversity of compounds II, by starting from one of the two components V or VI, already immobilized on the resin-support.

[0029] Specific compounds I prepared according to the process of the invention are reported in the following table:

Comp.	X	Z	Y	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆
1.	O	O	O	Ph	H	PhCH_2	H	H	COOH
2.	O	O	O	4-HO-Ph	H	PhCH_2	H	H	COOH
3.	O	O	O	4-O ₂ N-Ph	H	PhCH_2	H	H	COOH
4.	O	O	O	4-H ₂ N-Ph	H	PhCH_2	H	H	COOH
5.	O	O	O	4-MeO(O)C-Ph	H	PhCH_2	H	H	COOH
6.	O	O	O	4-Me-Ph	H	PhCH_2	H	H	COOH
7.	O	O	O	4-MeO-Ph	H	PhCH_2	H	H	COOH
8.	O	O	O	4-Cl-Ph	H	PhCH_2	H	H	COOH
9.	O	O	O	4-Br-Ph	H	PhCH_2	H	H	COOH
10.	O	O	O	2-HO-Ph	H	PhCH_2	H	H	COOH
11.	O	O	O	2-O ₂ N-Ph	H	PhCH_2	H	H	COOH
12.	O	O	O	2-H ₂ N-Ph	H	PhCH_2	H	H	COOH
13.	O	O	O	2-MeO(O)C-Ph	H	PhCH_2	H	H	COOH
14.	O	O	O	2-Me-Ph	H	PhCH_2	H	H	COOH
15.	O	O	O	2-MeO-Ph	H	PhCH_2	H	H	COOH
16.	O	O	O	2-Cl-Ph	H	PhCH_2	H	H	COOH
17.	O	O	O	2-Br-Ph	H	PhCH_2	H	H	COOH
18.	O	O	O	2-Naphthyl	H	PhCH_2	H	H	COOH
19.	O	O	O	2-thienyl	H	PhCH_2	H	H	COOH
20.	O	O	O	4-biphenyl	H	PhCH_2	H	H	COOH
21.	O	O	O	Ph	H	Me	H	H	COOH
22.	O	O	O	Ph	H	$\text{CH}_3(\text{CH}_2)_2$	H	H	COOH
23.	O	O	O	Ph	H	cyclohexyl	H	H	COOH
24.	O	O	O	Ph	H	allyl	H	H	COOH
25.	O	O	O	Ph	H	Ph	H	H	COOH
26.	O	O	O	Ph	H	4-HO-Ph	H	H	COOH

(continued)

Comp.	X	Z	Y	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆
27.	O	O	O	Ph	H	4-O ₂ N-Ph	H	H	COOH
28.	O	O	O	Ph	H	4-MeO ₂ C-Ph	H	H	COOH
29.	O	O	O	Ph	H	4-Me-Ph	H	H	COOH
30.	O	O	O	Ph	H	4-MeO-Ph	H	H	COOH
31.	O	O	O	Ph	H	4-Cl-Ph	H	H	COOH
32.	O	O	O	Ph	H	4-Br-Ph	H	H	COOH
33.	O	O	O	Ph	H	2-HO-Ph	H	H	COOH
34.	O	O	O	Ph	H	2-O ₂ N-Ph	H	H	COOH
35.	O	O	O	Ph	H	2-MeO ₂ C-Ph	H	H	COOH
36.	O	O	O	Ph	H	2-Me-Ph	H	H	COOH
37.	O	O	O	Ph	H	2-MeO-Ph	H	H	COOH
38.	O	O	O	Ph	H	2-Cl-Ph	H	H	COOH
39.	O	O	O	Ph	H	2-Br-Ph	H	H	COOH
40.	O	O	O	Ph	H	2-Nafthyl	H	H	COOH
41.	O	O	O	Ph	H	2-thienyl	H	H	COOH
42.	O	O	O	Ph	H	4-biphenyl	H	H	COOH
43.	O	O	O	Ph	H	4-MeO ₂ C-PhCH ₂	H	H	COOH
44.	O	O	O	Ph	H	4-Me-PhCH ₂	H	H	COOH
45.	O	O	O	Ph	H	4-MeOPhCH ₂	H	H	COOH
46.	O	O	O	Ph	H	4-Cl-PhCH ₂	H	H	COOH
47.	O	O	O	Ph	H	4-Br-PhCH ₂	H	H	COOH
48.	O	O	O	Ph	H	2-HO-PhCH ₂	H	H	COOH
49.	O	O	O	Ph	H	2-O ₂ N-PhCH ₂	H	H	COOH
50.	O	O	O	Ph	H	2-MeO ₂ C-PhCH ₂	H	H	COOH
51.	O	O	O	Ph	H	2-Me-PhCH ₂	H	H	COOH
52.	O	O	O	Ph	H	2-MeO-PhCH ₂	H	H	COOH
53.	O	O	O	Ph	H	2-Cl-PhCH ₂	H	H	COOH
54.	O	O	O	Ph	H	2-Br-PhCH ₂	H	H	COOH
55.	O	O	O	4-HO-Ph	H	4-HO-Ph CH ₂	H	H	COOH
56.	O	O	O	4-HO-Ph	H	4-O ₂ N-PhCH ₂	H	H	COOH
57.	O	O	O	4-HO-Ph	H	4-MeO ₂ C-PhCH ₂	H	H	COOH
58.	O	O	O	4-HO-Ph	H	4-Me-PhCH ₂	H	H	COOH
59.	O	O	O	4-HO-Ph	H	4-MeOPhCH ₂	H	H	COOH
60.	O	O	O	4-HO-Ph	H	4-Cl-PhCH ₂	H	H	COOH
61.	O	O	O	4-HO-Ph	H	4-Br-PhCH ₂	H	H	COOH
62.	O	O	O	4-HO-Ph	H	2-HO-PhCH ₂	H	H	COOH
63.	O	O	O	4-HO-Ph	H	2-O ₂ N-PhCH ₂	H	H	COOH
64.	O	O	O	4-HO-Ph	H	2-MeO ₂ C-PhCH ₂	H	H	COOH
65.	O	O	O	4-HO-Ph	H	2-Me-PhCH ₂	H	H	COOH
66.	O	O	O	4-HO-Ph	H	2-MeO-PhCH ₂	H	H	COOH
67.	O	O	O	4-HO-Ph	H	2-Cl-PhCH ₂	H	H	COOH
68.	O	O	O	4-HO-Ph	H	2-Br-PhCH ₂	H	H	COOH
69.	O	O	O	4-HO-Ph	H	Me	H	H	COOH
70.	O	O	O	4-HO-Ph	H	CH ₃ (CH ₂) ₂	H	H	COOH
71.	O	O	O	4-HO-Ph	H	cyclohexyl	H	H	COOH
72.	O	O	O	4-HO-Ph	H	allyl	H	H	COOH
73.	O	O	O	Ph	H	HO ₂ C-CH ₂	H	H	COOH
74.	O	O	O	Ph	H	Bn(HO ₂ C)CH	H	H	COOH
75.	O	O	O	Ph	H	HOCH ₂ (HO ₂ C)CH	H	H	COOH

(continued)

Comp.	X	Z	Y	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆
76.	O	O	O	Ph	H	CH ₃ (HO)CH(HO ₂ C)CH	H	H	COOH
77.	O	O	O	Ph	H	MeS(CH ₂) ₂ (HO ₂ C)CH	H	H	COOH
78.	O	O	O	Ph	H	H ₂ N(CH ₂) ₃ (HO ₂ C)CH	H	H	COOH
79.	O	O	O	Ph	H	HO ₂ CCH ₂ (HO ₂ C)CH	H	H	COOH
80.	O	O	O	Ph	H	imidazole-CH ₂ (HO ₂ C)CH	H	H	COOH
81.	O	O	O	Ph	H	indole-CH ₂ (HO ₂ C)CH	H	H	COOH
82.	O	O	O	4-HO-Ph	H	HO ₂ C-CH ₂	H	H	COOH
83.	O	O	O	4-HO-Ph	H	Me(HO ₂ C)CH	H	H	COOH
84.	O	O	O	4-HO-Ph	H	(CH ₃) ₂ CH(HO ₂ C)CH	H	H	COOH
85.	O	O	O	4-HO-Ph	H	Bn(HO ₂ C)CH	H	H	COOH
86.	O	O	O	4-HO-Ph	H	HOCH ₂ (HO ₂ C)CH	H	H	COOH
87.	O	O	O	4-HO-Ph	H	CH ₃ (HO)CH(HO ₂ C)CH	H	H	COOH
88.	O	O	O	4-HO-Ph	H	MeS(CH ₂) ₂ (HO ₂ C)CH	H	H	COOH
89.	O	O	O	4-HO-Ph	H	H ₂ N(CH ₂) ₃ (HO ₂ C)CH	H	H	COOH
90.	O	O	O	4-HO-Ph	H	HO ₂ CCH ₂ (HO ₂ C)CH	H	H	COOH
91.	O	O	O	4-HO-Ph	H	imidazole-CH ₂ (HO ₂ C)CH	H	H	COOH
92.	O	O	O	4-HO-Ph	H	indole-CH ₂ (HO ₂ C)CH	H	H	COOH
93.	O	O	O	Ph	Me	PhCH ₂	H	H	COOH
94.	O	O	O	4-HO-Ph	Me	PhCH ₂	H	H	COOH
95.	O	O	O	Ph	Bn	PhCH ₂	H	H	COOH
96.	O	O	O	4-HO-Ph	Bn	PhCH ₂	H	H	COOH
97.	O	O	O	Ph	Me	HO ₂ C-CH ₂	H	H	COOH
98.	O	O	O	4-HO-Ph	Me	HO ₂ C-CH ₂	H	H	COOH
99.	O	O	O	Ph	Bn	HO ₂ C-CH ₂	H	H	COOH
100.	O	O	O	4-HO-Ph	Bn	HO ₂ C-CH ₂	H	H	COOH
101.	O	O	O	Ph	Me	Bn(HO ₂ C)CH	H	H	COOH
102.	O	O	O	4-HO-Ph	Me	Bn(HO ₂ C)CH	H	H	COOH
103.	O	HN	O	Ph	H	PhCH ₂	H	H	CH ₃
104.	O	HN	O	Ph	Me	PhCH ₂	H	H	CH ₃
105.	O	HN	O	Ph	Bn	PhCH ₂	H	H	CH ₃
106.	O	HN	O	4-OH-Ph	H	PhCH ₂	H	H	CH ₃
107.	O	HN	O	4-OH-Ph	Me	PhCH ₂	H	H	CH ₃
108.	O	HN	O	4-OH-Ph	Bn	PhCH ₂	H	H	CH ₃
109.	O	HN	O	Ph	H	Ph	H	H	CH ₃
110.	O	HN	O	Ph	Me	Ph	H	H	CH ₃
111.	O	HN	O	Ph	Bn	Ph	H	H	CH ₃
112.	O	HN	O	4-OH-Ph	H	Ph	H	H	CH ₃
113.	O	HN	O	4-OH-Ph	Me	Ph	H	H	CH ₃
114.	O	HN	O	4-OH-Ph	Bn	Ph	H	H	CH ₃
115.	O	HN	O	Ph	H	CH ₃ -Ph	H	H	CH ₃
116.	O	HN	O	Ph	Me	CH ₃ -Ph	H	H	CH ₃
117.	O	HN	O	Ph	Bn	CH ₃ -Ph	H	H	CH ₃
118.	O	HN	O	4-OH-Ph	H	CH ₃ -Ph	H	H	CH ₃
119.	O	HN	O	4-OH-Ph	Me	CH ₃ -Ph	H	H	CH ₃
120.	O	HN	O	4-OH-Ph	Bn	CH ₃ -Ph	H	H	CH ₃
121.	O	HN	O	Ph	H	4-MeO-PhCH ₂	H	H	CH ₃
122.	O	HN	O	Ph	Me	4-MeO-PhCH ₂	H	H	CH ₃
123.	O	HN	O	Ph	Bn	4-MeO-PhCH ₂	H	H	CH ₃
124.	O	HN	O	4-OH-Ph	H	4-MeO-PhCH ₂	H	H	CH ₃

(continued)

Comp.	X	Z	Y	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆
125.	O	HN	O	4-OH-Ph	Me	4-MeO-PhCH ₂	H	H	CH ₃
126.	O	HN	O	4-OH-Ph	Bn	4-MeO-PhCH ₂	H	H	CH ₃
127.	O	HN	O	Ph	H	CH ₃ -PhCH ₂	H	H	CH ₃
128.	O	HN	O	Ph	Me	CH ₃ -PhCH ₂	H	H	CH ₃
129.	O	HN	O	Ph	Bn	CH ₃ -PhCH ₂	H	H	CH ₃
130.	O	HN	O	4-OH-Ph	H	CH ₃ -PhCH ₂	H	H	CH ₃
131.	O	HN	O	4-OH-Ph	Me	CH ₃ -PhCH ₂	H	H	CH ₃
132.	O	HN	O	4-OH-Ph	Bn	CH ₃ -PhCH ₂	H	H	CH ₃
133.	O	HN	O	Ph	H	Me	H	H	CH ₃
134.	O	HN	O	Ph	H	CH ₃ (CH ₂) ₂	H	H	CH ₃
135.	O	HN	O	Ph	H	cyclohexyl	H	H	CH ₃
136.	O	HN	O	Ph	H	allyl	H	H	CH ₃
137.	O	HN	O	4-OH-Ph	H	Me	H	H	CH ₃
138.	O	HN	O	4-OH-Ph	H	CH ₃ (CH ₂) ₂	H	H	CH ₃
139.	O	HN	O	4-OH-Ph	H	cyclohexyl	H	H	CH ₃
140.	O	HN	O	4-OH-Ph	H	allyl	H	H	CH ₃
141.	O	HN	O	Ph	H	HO ₂ C-CH ₂	H	H	CH ₃
142.	O	HN	O	Ph	Me	HO ₂ C-CH ₂	H	H	CH ₃
143.	O	HN	O	Ph	Bn	HO ₂ C-CH ₂	H	H	CH ₃
144.	O	HN	O	4-OH-Ph	H	HO ₂ C-CH ₂	H	H	CH ₃
145.	O	HN	O	4-OH-Ph	Me	HO ₂ C-CH ₂	H	H	CH ₃
146.	O	HN	O	4-OH-Ph	Bn	HO ₂ C-CH ₂	H	H	CH ₃
147.	O	HN	O	Ph	H	Bn(HO ₂ C)CH	H	H	CH ₃
148.	O	HN	O	Ph	Me	Bn(HO ₂ C)CH	H	H	CH ₃
149.	O	HN	O	Ph	Bn	Bn(HO ₂ C)CH	H	H	CH ₃
150.	O	HN	O	4-OH-Ph	H	Bn(HO ₂ C)CH	H	H	CH ₃
151.	O	HN	O	4-OH-Ph	Me	Bn(HO ₂ C)CH	H	H	CH ₃
152.	O	HN	O	4-OH-Ph	Bn	Bn(HO ₂ C)CH	H	H	CH ₃
153.	H	O	O	Ph	H	PhCH ₂	H	H	COOH
154.	H	O	O	Ph	Me	PhCH ₂	H	H	COOH
155.	H	O	O	Ph	Bn	PhCH ₂	H	H	COOH
156.	H	O	O	4-HO-Ph	H	PhCH ₂	H	H	COOH
157.	H	O	O	4-HO-Ph	Me	PhCH ₂	H	H	COOH
158.	H	O	O	4-HO-Ph	Bn	PhCH ₂	H	H	COOH
159.	H	O	O	Ph	H	HO ₂ C-CH ₂	H	H	COOH
160.	H	O	O	Ph	Me	HO ₂ C-CH ₂	H	H	COOH
161.	H	O	O	Ph	Bn	HO ₂ C-CH ₂	H	H	COOH
162.	H	O	O	4-HO-Ph	H	HO ₂ C-CH ₂	H	H	COOH
163.	H	O	O	4-HO-Ph	Me	HO ₂ C-CH ₂	H	H	COOH
164.	H	O	O	4-HO-Ph	Bn	HO ₂ C-CH ₂	H	H	COOH
165.	H	O	O	Ph	H	Bn(HO ₂ C)CH	H	H	COOH
166.	H	O	O	Ph	Me	Bn(HO ₂ C)CH	H	H	COOH
167.	H	O	O	Ph	Bn	Bn(HO ₂ C)CH	H	H	COOH
168.	H	O	O	4-HO-Ph	H	Bn(HO ₂ C)CH	H	H	COOH
169.	H	O	O	4-HO-Ph	Me	Bn(HO ₂ C)CH	H	H	COOH
170.	H	O	O	4-HO-Ph	Bn	Bn(HO ₂ C)CH	H	H	COOH
171.	H	HN	O	Ph	H	PhCH ₂	H	H	CH ₃
172.	H	HN	O	Ph	H	4-MeO-PhCH ₂	H	H	CH ₃
173.	H	HN	O	Ph	Me	PhCH ₂	H	H	CH ₃

(continued)

Comp.	X	Z	Y	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆
174.	H	HN	O	Ph	Bn	PhCH ₂	H	H	CH ₃
175.	H	HN	O	4-OH-Ph	H	PhCH ₂	H	H	CH ₃
176.	H	HN	O	4-OH-Ph	Me	PhCH ₂	H	H	CH ₃
177.	H	HN	O	4-OH-Ph	Bn	PhCH ₂	H	H	CH ₃
178.	H	HN	O	Ph	H	HO ₂ C-CH ₂	H	H	CH ₃
179.	H	HN	O	Ph	Me	HO ₂ C-CH ₂	H	H	CH ₃
180.	H	HN	O	Ph	Bn	HO ₂ C-CH ₂	H	H	CH ₃
181.	H	HN	O	4-OH-Ph	H	HO ₂ C-CH ₂	H	H	CH ₃
182.	H	HN	O	4-OH-Ph	Me	HO ₂ C-CH ₂	H	H	CH ₃
183.	H	HN	O	4-OH-Ph	Bn	HO ₂ C-CH ₂	H	H	CH ₃
184.	H	HN	O	Ph	H	Bn(HO ₂ C)CH	H	H	CH ₃
185.	H	HN	O	Ph	Me	Bn(HO ₂ C)CH	H	H	CH ₃
186.	H	HN	O	Ph	Bn	Bn(HO ₂ C)CH	H	H	CH ₃
187.	H	HN	O	4-OH-Ph	H	Bn(HO ₂ C)CH	H	H	CH ₃
188.	H	HN	O	4-OH-Ph	Me	Bn(HO ₂ C)CH	H	H	CH ₃
189.	H	HN	O	4-OH-Ph	Bn	Bn(HO ₂ C)CH	H	H	CH ₃
190.	H	HN	O	Ph	H	Ph	H	H	CH ₃
191.	H	HN	O	Ph	Me	Ph	H	H	CH ₃
192.	H	HN	O	Ph	Bn	Ph	H	H	CH ₃
193.	H	HN	O	4-OH-Ph	H	Ph	H	H	CH ₃
194.	H	HN	O	4-OH-Ph	Me	Ph	H	H	CH ₃
195.	H	HN	O	4-OH-Ph	Bn	Ph	H	H	CH ₃
196.	H	HN	O	Ph	H	CH ₃ -Ph	H	H	CH ₃
197.	H	HN	O	Ph	Me	CH ₃ -Ph	H	H	CH ₃
198.	H	HN	O	Ph	Bn	CH ₃ -Ph	H	H	CH ₃
199.	H	HN	O	4-OH-Ph	H	CH ₃ -Ph	H	H	CH ₃
200.	H	HN	O	4-OH-Ph	Me	CH ₃ -Ph	H	H	CH ₃
201.	H	HN	O	4-OH-Ph	Bn	CH ₃ -Ph	H	H	CH ₃
202.	H	HN	O	Ph	H	4-MeO-PhCH ₂	H	H	CH ₃
203.	H	HN	O	Ph	Me	4-MeO-PhCH ₂	H	H	CH ₃
204.	H	HN	O	Ph	Bn	4-MeO-PhCH ₂	H	H	CH ₃
205.	H	HN	O	4-OH-Ph	H	4-MeO-PhCH ₂	H	H	CH ₃
206.	H	HN	O	4-OH-Ph	Me	4-MeO-PhCH ₂	H	H	CH ₃
207.	H	HN	O	4-OH-Ph	Bn	4-MeO-PhCH ₂	H	H	CH ₃
208.	H	HN	O	Ph	H	CH ₃ -PhCH ₂	H	H	CH ₃
209.	H	HN	O	Ph	Me	CH ₃ -PhCH ₂	H	H	CH ₃
210.	H	HN	O	Ph	Bn	CH ₃ -PhCH ₂	H	H	CH ₃
211.	H	HN	O	4-OH-Ph	H	CH ₃ -PhCH ₂	H	H	CH ₃
212.	H	HN	O	4-OH-Ph	Me	CH ₃ -PhCH ₂	H	H	CH ₃
213.	H	HN	O	4-OH-Ph	Bn	CH ₃ -PhCH ₂	H	H	CH ₃
214.	H	O	O	Ph	H	PhCH ₂	H	H	CH ₂ OH
215.	H	O	O	Ph	H	4-MeOPhCH ₂	H	H	CH ₂ OH
216.	H	O	O	Ph	Me	PhCH ₂	H	H	CH ₂ OH
217.	H	O	O	Ph	Bn	PhCH ₂	H	H	CH ₂ OH
218.	H	O	O	4-HO-Ph	H	PhCH ₂	H	H	CH ₂ OH
219.	H	O	O	4-HO-Ph	Me	PhCH ₂	H	H	CH ₂ OH
220.	H	O	O	4-HO-Ph	Bn	PhCH ₂	H	H	CH ₂ OH
221.	H	O	O	Ph	H	HOCH ₂	H	H	CH ₂ OH
222.	H	O	O	Ph	Me	HOCH ₂	H	H	CH ₂ OH

(continued)

Comp.	X	Z	Y	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆
223.	H	O	O	Ph	Bn	HOCH ₂	H	H	CH ₂ OH
224.	H	O	O	4-HO-Ph	H	HOCH ₂	H	H	CH ₂ OH
225.	H	O	O	4-HO-Ph	Me	HOCH ₂	H	H	CH ₂ OH
226.	H	O	O	4-HO-Ph	Bn	HOCH ₂	H	H	CH ₂ OH
227.	H	O	O	Ph	H	Bn(HOCH ₂ C)CH	H	H	CH ₂ OH
228.	H	O	O	Ph	Me	Bn(HOCH ₂ C)CH	H	H	CH ₂ OH
229.	H	O	O	Ph	Bn	Bn(HOCH ₂ C)CH	H	H	CH ₂ OH
230.	H	O	O	4-HO-Ph	H	Bn(HOCH ₂ C)CH	H	H	CH ₂ OH
231.	H	O	O	4-HO-Ph	Me	Bn(HOCH ₂ C)CH	H	H	CH ₂ OH
232.	H	O	O	4-HO-Ph	Bn	Bn(HOCH ₂ C)CH	H	H	CH ₂ OH
233.	H	HN	O	Ph	H	PhCH ₂	H	H	H
234.	H	HN	O	Ph	H	4-MeO-PhCH ₂	H	H	H
235.	H	HN	O	Ph	Me	PhCH ₂	H	H	H
236.	H	HN	O	Ph	Bn	PhCH ₂	H	H	H
237.	H	HN	O	4-OH-Ph	H	PhCH ₂	H	H	H
238.	H	HN	O	4-OH-Ph	Me	PhCH ₂	H	H	H
239.	H	HN	O	4-OH-Ph	Bn	PhCH ₂	H	H	H
240.	H	HN	O	Ph	H	HOCH ₂	H	H	H
241.	H	HN	O	Ph	Me	HOCH ₂	H	H	H
242.	H	HN	O	Ph	Bn	HOCH ₂	H	H	H
243.	H	HN	O	4-OH-Ph	H	HOCH ₂	H	H	H
244.	H	HN	O	4-OH-Ph	Me	HOCH ₂	H	H	H
245.	H	HN	O	4-OH-Ph	Bn	HOCH ₂	H	H	H
246.	H	HN	O	Ph	H	Bn(HOCH ₂ C)CH	H	H	H
247.	H	HN	O	Ph	Me	Bn(HOCH ₂ C)CH	H	H	H
248.	H	HN	O	Ph	Bn	Bn(HOCH ₂ C)CH	H	H	H
249.	H	HN	O	4-OH-Ph	H	Bn(HOCH ₂ C)CH	H	H	H
250.	H	HN	O	4-OH-Ph	Me	Bn(HOCH ₂ C)CH	H	H	H
251.	H	HN	S	Ph	H	PhCH ₂	H	H	H
252.	H	HN	S	Ph	H	4-MeO-PhCH ₂	H	H	H
253.	H	HN	S	Ph	Me	PhCH ₂	H	H	H
254.	H	HN	S	Ph	Bn	PhCH ₂	H	H	H
255.	H	HN	S	4-OH-Ph	H	PhCH ₂	H	H	H
256.	H	HN	S	4-OH-Ph	Me	PhCH ₂	H	H	H
257.	H	HN	S	4-OH-Ph	Bn	PhCH ₂	H	H	H
258.	H	HN	S	Ph	H	HOCH ₂	H	H	H
259.	H	HN	S	Ph	Me	HOCH ₂	H	H	H
260.	H	HN	S	Ph	Bn	HOCH ₂	H	H	H
261.	H	HN	S	4-OH-Ph	H	HOCH ₂	H	H	H
262.	H	HN	S	4-OH-Ph	Me	HOCH ₂	H	H	H
263.	H	HN	S	4-OH-Ph	Bn	HOCH ₂	H	H	H
264.	H	HN	S	Ph	H	Bn(HOCH ₂ C)CH	H	H	H
265.	H	HN	S	Ph	Me	Bn(HOCH ₂ C)CH	H	H	H
266.	H	HN	S	Ph	Bn	Bn(HOCH ₂ C)CH	H	H	H
267.	H	HN	S	4-OH-Ph	H	Bn(HOCH ₂ C)CH	H	H	H
268.	H	HN	S	4-OH-Ph	Me	Bn(HOCH ₂ C)CH	H	H	H

[0030] The invention will be better understood in the light of the following Examples.

EXAMPLE 1

Preparation of *N*-benzyl-*N*-[2-oxo-2-phenylethyl]-(2*R*,3*R*)-2,3-di-*O*-isopropylidenetartramic Acid Methyl Ester [compound IV wherein $R_1 = \text{Ph}$, $R_2 = \text{H}$, $R_3 = \text{PhCH}_2$, $R_4 = \text{H}$, $R_5 = \text{H}$, $R_6 = \text{COOMe}$, $Z = \text{O}$, $Y = \text{O}$, $R_7-R_8 = \text{CH}_2-\text{CH}_2$]

[0031] To a solution of II (wherein $R_1 = \text{Ph}$, $R_2 = \text{H}$, $R_3 = \text{PhCH}_2$) (1.2 g, 5.33 mmol) in anhydrous CH_2Cl_2 (10 ml) (CH_2Cl_2 was filtered through a short pad of anhydrous Na_2CO_3 just before being used) were added, under a nitrogen atmosphere, III (wherein $R_4 = \text{H}$, $R_5 = \text{H}$, $R_6 = \text{COOMe}$, $Z = \text{O}$, $Y = \text{O}$, $R_7-R_8 = \text{CH}_2-\text{CH}_2$) (1.088 g, 5.33 mmol), PyBrOP (2.49 g, 5.33 mmol), and DIPEA (2.73 mL, 15.99 mmol). The mixture was stirred at room temperature for 2 h, and then the solvent was removed to give an oil that was dissolved in EtOAc. This solution was washed with aqueous 5% KHSO_4 , 5% NaHCO_3 , and brine and dried over Na_2SO_4 . After evaporation of the solvent, the crude product obtained was purified by chromatography (EtOAc-petroleum ether, 1:3, Rf 0.32), yielding IV (wherein $R_1 = \text{Ph}$, $R_2 = \text{H}$, $R_3 = \text{PhCH}_2$, $R_4 = \text{H}$, $R_5 = \text{H}$, $R_6 = \text{COOMe}$, $Z = \text{O}$, $Y = \text{O}$, $R_7-R_8 = \text{CH}_2-\text{CH}_2$) (1.645 g, 75%) as a colorless oil:
 $^1\text{H NMR}$ (CDCl_3): 7.90-7.85 (m, 2H), 7.61-7.22 (m, 8H), 5.39 (d, $J = 5.1$ Hz, 1H), 5.11 (d, $J = 5.1$ Hz, 1H), 4.88-4.10 (m, 4H), 3.80 (s, 3H), 1.49 (s, 3H), 1.31 (s, 3H).

EXAMPLE 2

Preparation of Methyl (1*R*,5*S*,7*R*)-3-Benzyl-2-oxo-5-phenyl-6,8-dioxo-3-azabicyclo[3.2.1]octane-7-*exo*-carboxylate [compound I wherein $R_1 = \text{Ph}$, $R_2 = \text{H}$, $R_3 = \text{PhCH}_2$, $R_4 = \text{H}$, $R_5 = \text{H}$, $R_6 = \text{COOMe}$, $X = \text{O}$, $Z = \text{O}$, $Y = \text{O}$]

[0032] A solution of IV (prepared according to the example 1, wherein $R_1 = \text{Ph}$, $R_2 = \text{H}$, $R_3 = \text{PhCH}_2$, $R_4 = \text{H}$, $R_5 = \text{H}$, $R_6 = \text{COOMe}$, $Z = \text{O}$, $Y = \text{O}$, $R_7-R_8 = \text{CH}_2-\text{CH}_2$) (1.645 g, 4.00 mmol) in toluene (40 mL) was quickly added to a refluxing suspension of $\text{H}_2\text{SO}_4/\text{SiO}_2$ (30% w/w, 700 mg) in toluene (60 mL). The mixture was allowed to react for 15 min, and afterward, one-third of the solvent was distilled off. The hot reaction mixture was filtered through a short layer of NaHCO_3 , and after evaporation of the solvent, the crude product was purified by chromatography as above affording pure I (wherein $R_1 = \text{Ph}$, $R_2 = \text{H}$, $R_3 = \text{PhCH}_2$, $R_4 = \text{H}$, $R_5 = \text{H}$, $R_6 = \text{COOMe}$, $X = \text{O}$, $Z = \text{O}$, $Y = \text{O}$) (1.200 g, 85%); mp 112-114 °C;
 $[\alpha]_D^{25} - 64.3$ (c 0.8, CDCl_3);
 $^1\text{H NMR}$ (CDCl_3): 7.62-7.59 (m, 2H), 7.41-7.24 (m, 8H), 5.16 (s, 1H), 4.92 (s, 1H), 4.61 (AB system, $J = 11.0$ Hz, 2H), 3.74 (s, 3H), 3.46 (AB system, $J = 25.2$ Hz, 2H).
 $^{13}\text{C NMR}$ (CDCl_3): 169.0 (s), 165.4 (s), 137.8 (s), 135.0 (s), 129.5 (d), 128.8 (d), 128.3 (d), 127.9, 127.8 (d), 125.4 (d), 107.7 (s), 79.1 (d), 78.3 (d), 55.5 (t), 52.6 (q), 48.6 (t)
 $\text{IR}(\text{CDCl}_3)$: 1762, 1678 cm^{-1}
 $\text{MS} (m/z, \%)$: 353 (M^+ , 3), 147 (5), 120 (36), 306 (13), 105 (80), 91 (100).

EXAMPLE 3

Preparation of *N*-(*p*-Methoxybenzyl)-*N*-[2-oxo-2-phenylethyl]-(2*R*,3*R*)-2,3-di-*O*-isopropylidenetartramic Acid Methyl Ester [compound IV, wherein $R_1 = \text{Ph}$, $R_2 = \text{H}$, $R_3 = 4\text{-MeO-C}_6\text{H}_4\text{CH}_2$, $R_4 = \text{H}$, $R_5 = \text{H}$, $R_6 = \text{COOMe}$, $Z = \text{O}$, $Y = \text{O}$, $R_7-R_8 = \text{CH}_2-\text{CH}_2$]

[0033] A solution of II (wherein $R_1 = \text{Ph}$, $R_2 = \text{H}$, $R_3 = 4\text{-MeO-C}_6\text{H}_4\text{CH}_2$) (0.5 g, 2.09 mmol) in anhydrous CH_2Cl_2 (5 ml), III (wherein $R_4 = \text{H}$, $R_5 = \text{H}$, $R_6 = \text{COOMe}$, $Z = \text{O}$, $Y = \text{O}$, $R_7-R_8 = \text{CH}_2-\text{CH}_2$) (0.427 g, 2.09 mmol), PyBrOP (0.976 g, 2.09 mmol), and DIPEA (1.07 mL, 6.27 mmol) was treated as in the example 1. The crude product obtained was purified by chromatography (EtOAc-petroleum ether, 1:3, Rf 0.32), yielding IV (wherein $R_1 = \text{Ph}$, $R_2 = \text{H}$, $R_3 = 4\text{-MeO-C}_6\text{H}_4\text{CH}_2$, $R_4 = \text{H}$, $R_5 = \text{H}$, $R_6 = \text{COOMe}$, $Z = \text{O}$, $Y = \text{O}$, $R_7-R_8 = \text{CH}_2-\text{CH}_2$) (0.370 g, 40%) as a colorless oil:
 $^1\text{H NMR}$ (CDCl_3): 7.90-7.85 (m, 2H), 7.61-7.43 (m, 3H), 7.21-7.15 (m, 2H), 6.90-6.82 (m, 2H), 5.39 (d, $J = 5.1$ Hz, 1H), 5.13 (d, $J = 5.1$ Hz, 1H), 4.75 (m, 2H), 4.11 (m, 2H), 3.82 (s, 3H), 3.79 (s, 3H), 1.52 (s, 3H), 1.36 (s, 3H).

EXAMPLE 4

[0034] Preparation of Methyl (1*R*,5*S*,7*R*)-3-(*p*-Methoxybenzyl)-2-oxo-5-phenyl-6,8-dioxo-3-azabicyclo[3.2.1]octane-7-*exo*-carboxylate [compound I wherein $R_1 = \text{Ph}$, $R_2 = \text{H}$, $R_3 = 4\text{-MeO-C}_6\text{H}_4\text{CH}_2$, $R_4 = \text{H}$, $R_5 = \text{H}$, $R_6 = \text{COOMe}$, $X = \text{O}$, $Z = \text{O}$, $Y = \text{O}$]

[0035] A solution of IV (wherein $R_1 = \text{Ph}$, $R_2 = \text{H}$, $R_3 = 4\text{-MeO-C}_6\text{H}_4\text{CH}_2$, $R_4 = \text{H}$, $R_5 = \text{H}$, $R_6 = \text{COOMe}$, $Z = \text{O}$, $Y = \text{O}$, $R_7-R_8 = \text{CH}_2-\text{CH}_2$) (0.370 g, 0.84 mmol) in toluene (10 mL) was treated as reported in example 2. The crude product was purified by chromatography as above affording pure I (wherein $R_1 = \text{Ph}$, $R_2 = \text{H}$, $R_3 = 4\text{-MeO-C}_6\text{H}_4\text{CH}_2$, $R_4 = \text{H}$,

$R_5 = H$, $R_6 = COOMe$, $X = O$, $Z = O$, $Y = O$ (0.177 g, 55 %): mp 134 - 136 °C;

$[\alpha]_D^{25} - 62.3$ (c 0.6, $CDCl_3$);

1H NMR ($CDCl_3$) 7.62-7.59 (m, 2H), 7.41-7.24 (m, 5H), 7.11-6.91 (m, 2H), 5.14 (s, 1 H), 4.89 (s, 1 H), 4.24 (AB system, $J = 11.0$ Hz, 2H), 3.78 (s, 3 H), 3.74 (s, 3

[0036] H), 3.56 (AB system, $J = 23.4$ Hz, 2H).

^{13}C NMR ($CDCl_3$): 169.4 (s), 165.3 (s), 159.8 (s), 137.8 (s), 135.0 (s), 129.5 (d), 128.1 (d), 127.1 (d), 126.4 (d), 119.2 (d), 107.1 (s), 79.8 (d), 78.0 (d), 58.5 (t), 55.1 (q), 52.6 (q), 48.1 (t).

IR ($CDCl_3$): 1768, 1682 cm^{-1}

MS (m/z , %): 383 (M^+ , 5), 121 (100).

EXAMPLE 5

Preparation of (1*R*,5*S*,7*R*)-3-Benzyl-2-oxo-5-(4-hydroxyphenyl)-6,8-dioxo-3-azabicyclo[3.2.1]octane-7-*exo*-carboxylic Acid [compound I wherein $R_1 = 4-OH-C_6H_4$, $R_2 = H$, $R_3 = PhCH_2$, $R_4 = H$, $R_5 = H$, $R_6 = COOH$, $X = O$, $Z = O$, $Y = O$]

[0037] Wang resin (1 g, 200-400 mesh, substitution 0.64 mmol/g) was suspended in CH_2Cl_2 (10 mL) and magnetically stirred for 15 min. After filtration, a solution of Ph_3P (1.024g, 3.904 mmol) and 4'-hydroxy-2-chloroacetophenone (compound V wherein $Hal = Cl$, $R_1 = 4-OH-C_6H_4$, $R_2 = H$), (0.568 g, 3.33 mmol) in a mixture of CH_2Cl_2 (10 mL) and Et_2O (4 mL) was added to the expanded resin. After 5 min, DEAD (607 mL, 3.904 mmol) was added drop-wise and the resulting suspension stirred at room temperature. After 24 h the suspension was filtered and the resin washed with DMF (3 x 10 mL), CH_2Cl_2 (3 x 10 mL), MeOH (3 x 10 mL) and again DMF (3 x 10 mL). Then, the resin (1.00 g), suspended in CH_2Cl_2 (1 mL), was treated with benzylamine (compound VI wherein $R_3 = PhCH_2$) (10 mL) and left under stirring at room temperature for 12 h. After filtration, the resin II ($R_1 = Wang-4-OH-C_6H_4$, $R_2 = H$, $R_3 = PhCH_2$) obtained was washed as above with DMF, CH_2Cl_2 , MeOH and again DMF. Resin II ($R_1 = Wang-4-OH-C_6H_4$, $R_2 = H$, $R_3 = PhCH_2$) was then coupled with III [wherein $R_4 = H$, $R_5 = H$, $R_6 = COOMe$, $Z = O$, $Y = O$, $R_7-R_8 = CH_2-CH_2$] as follows: compound III (261 mg, 1.28 mmol) and PyBroP (597 mg, 1.28 mmol) were added to resin II (500 mg) suspended in DMF (10 mL), then DIPEA (438 μ L, 1.28 mmol) was added slowly at room temperature and the resulting suspension stirred for 12 h. After the usual work-up, resin IV [$R_1 = Wang-4-OH-C_6H_4$, $R_2 = H$, $R_3 = PhCH_2$, $R_4 = R_5 = H$, $R_6 = COOMe$, $Z = O$, $Y = O$, $R_7-R_8 = CH_2-CH_2$] was obtained. The cyclization step was performed on 250 mg of resin IV as follows: resin IV (250 mg) and *p*-TsOH (6 mg) were suspended in toluene and the mixture refluxed for 15 min. Then part of the solvent (25 mL) was distilled off and the residual suspension filtered. The solution was concentrated obtaining, as a yellow oil, compound I [wherein $R_1 = 4-OH-C_6H_4$, $R_2 = H$, $R_3 = PhCH_2$, $R_4 = H$, $R_5 = H$, $R_6 = COOH$, $X = O$, $Z = O$, $Y = O$] (33 mg), with complete cleavage from the resin.

1H NMR ($CDCl_3$) δ : 7.78 (d, $J = 8.8$ Hz, 2 H), 7.60 (d, $J = 7.2$ Hz, 2 H), 7.40-7.00 (m, 3 H), 6.80 (d, $J = 8.8$ Hz, 2 H), 5.13 (s, 1 H), 4.86 (s, 1 H), 4.58 (AB system, $J = 15.0$ Hz, 2 H), 3.57 (d, $J = 11.8$ Hz, 1 H), 3.38 (d, $J = 11.8$ Hz, 1 H).

EXAMPLE 6

Preparation of *N*-(4-methylphenyl)-*N*-[2-oxo-2-phenylethyl]-(2*R*,3*R*)-2,3-di-*O*-isopropylidenetartramic Acid Methyl Ester [compound IV wherein $R_1 = Ph$, $R_2 = H$, $R_3 = 4-Me-C_6H_4$, $R_4 = H$, $R_5 = H$, $R_6 = COOMe$, $Z = O$, $Y = O$, $R_7-R_8 = CH_2-CH_2$]

[0038] To a solution of III (wherein $R_4 = H$, $R_5 = H$, $R_6 = COOMe$, $Z = O$, $Y = O$, $R_7-R_8 = CH_2-CH_2$) (366 mg, 1.8 mmol) in methylene chloride (1.8 ml) and PyBroP (839 mg, 1.8 mmol) was added II (wherein $R_1 = Ph$, $R_2 = H$, $R_3 = 4-Me-C_6H_4$) (406mg, 1.8 mmol) and DIPEA (0.765 mL, 3.6 mmol). The mixture was treated as reported in Example 1. The crude product was purified by column chromatography on silica gel (AcOEt- Petroleum Ether. 1:2, $R_f = 0.37$) to give IV ($R_1 = Ph$, $R_2 = H$, $R_3 = 4-Me-C_6H_4$, $R_4 = R_5 = H$, $R_6 = COOMe$, $Z = O$, $Y = O$, $R_7-R_8 = CH_2-CH_2$) as yellow oil (440 mg, 62%).

1H NMR δ 8.00-7.90 (m, 2H), 7.62-7.39 (m, 4H), 7.36-7.12 (m, 3H), 5.26 ($J = 17.2$ Hz part A of AB system, 1H) 4.96 ($J = 17.2$ Hz part B of AB system, 1H), 5.07 ($J = 6.6$ Hz part A of AB system, 1 H) 4.66 ($J = 6.6$ Hz part B of AB system, 1 H), 3.74 (s, 3H), 2.36 (s, 3H), 1.53 (s, 3H), 1.36 (s, 3H). MS (m/z , %): 411 (M^+ , 4), 352 (6), 306 (13), 120(100).

EXAMPLE 7

Preparation of Methyl (1*R*,5*S*,7*R*)-3-(4'-methylphenyl)-2-oxo-5-phenyl-6,8-dioxo-3-azabicyclo[3.2.1]octane-7-*exo*-carboxylate [compound I wherein $R_1 = Ph$, $R_2 = H$, $R_3 = 4-Me-C_6H_4$, $R_4 = H$, $R_5 = H$, $R_6 = COOMe$, $X = O$, $Z = O$, $Y = O$]

[0039] A solution of IV (prepared in the example 6, wherein $R_1 = Ph$, $R_2 = H$, $R_3 = 4-Me-C_6H_4$, $R_4 = H$, $R_5 = H$, $R_6 =$

COOMe, Z = O, Y = O, R₇—R₈ = CH₂—CH₂) (310 mg, 0.75 mmol) in toluene (32 ml) was quickly added to a refluxing solution of H₂SO₄/SiO₂ (175 mg) in toluene (16 ml). The mixture was treated as reported in Example 2. The product I [wherein R₁ = Ph, R₂ = H, R₃ = 4-Me-C₆H₄, R₄ = H, R₅ = H, R₆ = COOMe, X = O, Z = O, Y = O] was obtained in pure form (260 mg, 97%).

¹H NMR δ: 7.78-7.66 (m, 2H), 7.48-7.36 (m, 4H), 7.30-7.10 (m, 3H), 5.23 (s, 1 H), 5.02 (s, 1H), 4.02 (J=12 Hz part A of AB system, 1H) 3.90 (J=12 Hz part B of AB system, 1H), 3.73 (s, 3H), 2.35 (s, 3H). ¹³C NMR δ: 168.9(s), 165.1(s), 137.4 (s), 136.8 (s), 135.1(s), 129.9 (d), 129.6 (d), 128.4 (d), 125.4 (d), 125.3(d), 107.6 (s), 79.4 (d), 78.4 (d), 59.2 (t), 52.7 (q), 20.9 (q). MS (m/z, %): 353 (M⁺, 4), 294 (2), 119 (100).

EXAMPLE 8

Preparation of *N*[(1*S*)-(1-carbomethoxy-2-phenylethyl)]-*N*-[2-oxo-2-phenylethyl]-(2*R*,3*R*)-2,3-di-*O*-isopropylidenetartramic Acid Methyl Ester [compound IV wherein R₁ = Ph, R₂ = H, R₃ = CH(COOMe)CH₂Ph, R₄=H, R₅=H, R₆=COOMe, Z=O, Y=O, R₇—R₈=CH₂—CH₂].

[0040] To a solution of III (wherein R₄=H, R₅=H, R₆=COOMe, Z=O, Y=O, R₇—R₈=CH₂—CH₂) (118 mg, 0.58 mmol) in CH₂Cl₂ (0.5 mL), and PyBrOP (270 mg, 0.58 mmol) was added II (wherein R₁ = Ph, R₂ = H, R₃ = CH(COOMe)CH₂Ph) (120 mg, 0.4 mmol) and DIPEA (0.255 mL, 1.2 mmol). The mixture was treated as reported in Example 1. The crude product was purified by column chromatography on silica gel (CH₂Cl₂- MeOH (40:1) to afford IV (wherein R₁ = Ph, R₂ = H, R₃ = CH(COOMe)CH₂Ph, R₄=H, R₅=H, R₆=COOMe, Z=O, Y=O, R₇—R₈=CH₂—CH₂) (160mg, 82%).

[0041] The ¹H and ¹³C NMR spectrums show two set of signals in 2:1 ratio. ¹H NMR (CDCl₃) δ: 8.04-7.90 (m, 2H), 7.70-7.42 (m, 4H), 7.38-7.20 (m, 4H), 5.48-4.74 (m, 5H), 3.76 and 3.75 (s, 3H), 3.59 (s, 3H), 3.38-3.30 (m, 2H), 1.56 and 1.46, 1.33, 1.28 (s, 6H). ¹³C NMR (CDCl₃) δ: 193.6, 192.3, 170.7, 170.6, 169.9, 169.4, 168.5, 136.6, 135.9, 135.0, 134.5, 133.7, 129.1, 129.0, 128.7, 128.5, 128.4, 128.3, 127.8, 127.6, 126.8, 126.6, 113.2, 77.2, 76.9, 75.4, 60.3, 59.3, 52.5, 52.3, 51.7, 49.2, 36.4, 35.6, 26.5, 26.3, 26.2, 25.9. MS m/z (%): 483 (M⁺, 2), 424 (4), 378 (7), 320 (16), 206 (34), 192 (50), 162 (63), 105 (100)

EXAMPLE 9

Preparation of Methyl (1*R*,5*S*,7*R*)-3-[(1*S*)-1-carbomethoxy-2-phenylethyl]-2-oxo-5-phenyl-6,8-dioxo-3-azabicyclo [3.2.1]octane-7-exo-carboxylate [compound I wherein R₁ = Ph, R₂ = H, R₃ = CH(COOMe)CH₂Ph, R₄ = H, R₅ = H, R₆ = COOMe, X = O, Z = O, Y = O]

[0042] A solution of IV (prepared according the example 8, wherein R₁ = Ph, R₂ = H, R₃ = CH(COOMe)CH₂Ph, R₄=H, R₅=H, R₆=COOMe, Z=O, Y=O, R₇—R₈=CH₂—CH₂) (150 mg, 0.30 mmol) in toluene (5 ml) was quickly added to a refluxing solution of H₂SO₄/SiO₂ (60 mg) in toluene (33 ml) The mixture was treated as reported in Example 2. The crude product was purified by flash chromatography (AcOEt-Petroleum Ether 1:1, R_f= 0.41) to afford I (wherein R₁ = Ph, R₂ = H, R₃ = CH(COOMe)CH₂Ph, R₄ = H, R₅ = H, R₆ = COOMe, X = O, Z = O, Y = O) as 2:1 mixture of eplimers (82 mg, 65%).

¹H NMR (CDCl₃) major epimer: δ 7.60 (m, 2 H), 7.90-7.30 (m, 8 H), 5.11 (dd, J= 5.6, 10.8 Hz, 1 H), 4.99 (s, 1 H), 4.84 (s 1 H), 3.78 (s, 3 H), 3.72 (s, 3 H), 3.75-3.34 (m, 3 H), 3.08 (m, 1 H). MS m/z (%): 425 (M⁺, 2), 366 (19), 306 (7), 192 (32), 105 (100), 91 (88), 77 (62).

EXAMPLE 10

Preparation of *N*-Boc *N*-(4-methoxybenzyl)-*N*-[2-oxo-2-phenylethyl]threoninamide IV (wherein R₁ = Ph, R₂ = H, R₃ = *p*-CH₃O-C₆H₄CH₂, R₄ = H, R₅ = H, R₆=Me, R₇= Boc, R₈=H, Z=N, Y=O).

[0043] To a solution of III (R₄ = H, R₅ = H, R₆ = Me, R₇ = Boc, R₈ = H, Z = N, Y = O) in CH₂Cl₂ (5 mL) and PyBrOP (531 mg, 1.14 mmol) was added II (wherein R₁ = Ph, R₂ = H, R₃ = *p*-CH₃O-C₆H₄CH₂) (333 mg, 1.14 mmol) and DIPEA (0.585 mL, 3.42 mmol). The mixture The mixture was treated as reported in Example 1. The crude product was purified by column chromatography on silica gel (EtOAc-petrolrum ether, 1:1.5, R_f= 0.23) to afford IV (wherein R₁ = Ph, R₂ = H, R₃ = *p*-CH₃O-C₆H₄CH₂, R₄ = H, R₅ = H, R₆ = Me, R₇ = Boc, R₈ = H, Z = N, Y = O) (232 mg, 44%) as an oil.

¹H NMR (CDCl₃) (1:1 mixture of rotamers) δ 7.85 (d, J = 7.3 Hz, 2 H), 7.55 (m, 1 H), 7.42 (m, 2 H), 7.11 (m, 2 H), 6.82 (m, 2 H), 5.50 (m, 1 H), 5.29 (d, J = 14.3 Hz, 1 H), 5.00-4.20 (m, 5 H), 4.00 (m, 1 H), 3.78 (s, 3 H), 3.76 (s, 3 H), 1.38 (s, 9 H), 1.31 (s, 9 H), 1.19 (d, J = 6.2 Hz, 3 H), 1.07 (d, J = 6.2 Hz, 3 H).

EXAMPLE 11

Preparation of (1*R*,5*S*,7*R*)-3-(4-methoxybenzyl)-2-oxo-5-phenyl-7-exo-methyl-6-oxa-3,8-diazabicyclo[3.2.1]octane [compound I wherein $R_1 = \text{Ph}$, $R_2 = \text{H}$, $R_3 = p\text{-CH}_3\text{O-C}_6\text{H}_4\text{CH}_2$, $R_4 = \text{H}$, $R_5 = \text{H}$, $R_6 = \text{Me}$, $X = \text{O}$, $Z = \text{N}$, $Y = \text{O}$]

[0044] A solution of IV (wherein $R_1 = \text{Ph}$, $R_2 = \text{H}$, $R_3 = p\text{-CH}_3\text{O-C}_6\text{H}_4\text{CH}_2$, $R_4 = \text{H}$, $R_5 = \text{H}$, $R_6 = \text{Me}$, $R_7 = \text{Boc}$, $R_8 = \text{H}$, $Z = \text{N}$, $Y = \text{O}$) (78.3 mg, 0.172 mmol) and *p*-TsOH (36 mg, 0.189 mmol) in benzene (10 ml) is refluxed for 30 min, then 8 ml of solvent were distilled off. The resulting solution was concentrated obtaining compound I (I wherein $R_1 = \text{Ph}$, $R_2 = \text{H}$, $R_3 = p\text{-CH}_3\text{O-C}_6\text{H}_4\text{CH}_2$, $R_4 = \text{H}$, $R_5 = \text{H}$, $R_6 = \text{Me}$, $X = \text{O}$, $Z = \text{N}$, $Y = \text{O}$) as *p*-TsOH salt (60 mg, 76%). This was treated with 0.1 M aqueous solution of KOH and the free amine extracted with CHCl_3 to give, after concentration, compound I (I wherein $R_1 = \text{Ph}$, $R_2 = \text{H}$, $R_3 = p\text{-CH}_3\text{O-C}_6\text{H}_4\text{CH}_2$, $R_4 = \text{H}$, $R_5 = \text{H}$, $R_6 = \text{Me}$, $X = \text{O}$, $Z = \text{N}$, $Y = \text{O}$) as a colorless oil (41 mg, 70%).

$^1\text{H NMR}$ (CDCl_3) δ 7.70 (m, 2 H), 7.52-7.20 (m, 5 H), 6.83 (m, 2 H), 5.07 (s, 1 H), 4.79 (d, $J = 14.1$ Hz, 1 H), 4.55 (d, $J = 14.1$ Hz, 1 H), 3.78 (s, 3 H), 3.78 (m, 2 H), 2.84 (q, $J = 7.4$ Hz, 1 H), 1.60 (d, $J = 7.4$ Hz, 3 H).

EXAMPLE 12

Preparation of (1*S*,5*S*,7*S*)-3-benzyl-5-phenyl-7-exo-hydroxymethyl-6,8-dioxo-3-azabicyclo[3.2.1]octane [compound I wherein $R_1 = \text{Ph}$, $R_2 = \text{H}$, $R_3 = \text{PhCH}_2$, $R_4 = \text{H}$, $R_5 = \text{H}$, $R_6 = \text{CH}_2\text{OH}$, $X = \text{H}$, $Z = \text{O}$, $Y = \text{O}$]

[0045] To a suspension of LiAlH_4 (50 mg, mmol) in anhydrous THF (10 mL) was added dropwise at 0 °C and under nitrogen atmosphere a solution of compound I, [prepared according to the example 2, wherein $R_1 = \text{Ph}$, $R_2 = \text{H}$, $R_3 = \text{PhCH}_2$, $R_4 = \text{H}$, $R_5 = \text{H}$, $R_6 = \text{COOMe}$, $X = \text{O}$, $Z = \text{O}$, $Y = \text{O}$] (22 mg, 0.568 mmol) in dry THF (12 ml). The mixture was refluxed for 2h, and then, after cooling to 0 °C, diethyl ether (2 mL) were added. The mixture was filtered through a short layer of anhydrous Na_2SO_4 , and the residue was suspended in 1 M KOH solution (30 mL), saturated with NaCl, and extracted with Et_2O and EtOAc . The organic phases were combined, dried over anhydrous Na_2SO_4 and concentrated to give compound I (wherein $R_1 = \text{Ph}$, $R_2 = \text{H}$, $R_3 = \text{PhCH}_2$, $R_4 = \text{H}$, $R_5 = \text{H}$, $R_6 = \text{CH}_2\text{OH}$, $X = \text{H}$, $Z = \text{O}$, $Y = \text{O}$) as a colorless oil (35 mg, 0.112 mmol, 79 %).

$^1\text{H NMR}$ (CDCl_3) δ 7.53-7.30 (m, 2 H), 7.29-7.23 (m, 8 H), 4.66-4.34 (m, 2 H), 3.34-3.46 (m, 4 H), 3.06-2.43 (m, 4 H), 1.82 (br s, 1 H).


EXAMPLE 13

Preparation of Methyl (1*R*,5*S*,7*R*)-3-[(1*S*)-1-carbomethoxy-2-phenylethyl]-2-oxo-5-phenyl-6,8-dioxo-3-azabicyclo[3.2.1]octane-7-exo-carboxylate [compound I wherein $R_1 = \text{Ph}$, $R_2 = \text{H}$, $R_3 = \text{CH}(\text{COOMe})\text{CH}_2\text{Ph}$, $R_4 = \text{H}$, $R_5 = \text{H}$, $R_6 = \text{COOMe}$, $X = \text{O}$, $Z = \text{O}$, $Y = \text{O}$]


[0046] Fmoc-(*S*)-phenylalanine-O-Wang resin (2 g, 200-400 mesh, substitution 1 mmol/g) was treated with piperidine (30%) in DMF (10 mL) under stirring, for 15 min, to obtain compound VI (wherein $R_3 = \text{CH}(\text{COO-Wang resin})\text{CH}_2\text{Ph}$). After filtration, the resin suspended in DMF (10 mL), was treated with 2-bromo-acetophenone (compound V wherein $\text{Hal} = \text{Br}$, $R_1 = \text{Ph}$, $R_2 = \text{H}$), (1.09 g, 6.0 mmol) and DIPEA (340 μL , 2 mmol) and left under stirring at room temperature for 48 h. The resin II [$R_1 = \text{Ph}$, $R_2 = \text{H}$, $R_3 = \text{CH}(\text{COO-Wang resin})\text{CH}_2\text{Ph}$] obtained was washed as reported in example 5 with DMF, CH_2Cl_2 , MeOH and again DMF. Resin II [$R_1 = \text{Ph}$, $R_2 = \text{H}$, $R_3 = \text{CH}(\text{COO-Wang resin})\text{CH}_2\text{Ph}$] was then coupled with III [wherein $R_4 = \text{H}$, $R_5 = \text{H}$, $R_6 = \text{COOMe}$, $Z = \text{O}$, $Y = \text{O}$, $R_7\text{---}R_8 = \text{CH}_2\text{---CH}_2$] as follows: compound III (816 mg, 4 mmol) and PyBroP (1.86 g, 4 mmol) were added to resin II (1.00 g) suspended in DMF (10 mL), then DIPEA (680 μL , 4 mmol) was added slowly at room temperature and the resulting suspension stirred for 12 h. After the usual work-up, resin IV [$R_1 = \text{Ph}$, $R_2 = \text{H}$, $R_3 = \text{CH}(\text{COO-Wang resin})\text{CH}_2\text{Ph}$, $R_4 = \text{H}$, $R_5 = \text{H}$, $R_6 = \text{COOMe}$, $Z = \text{O}$, $Y = \text{O}$, $R_7\text{---}R_8 = \text{CH}_2\text{---CH}_2$] was obtained. The cyclization step was performed on 1 g of resin IV as follows: resin IV (1 g) and *p*-TsOH (95 mg) were suspended in toluene and the mixture refluxed for 15 min. Then part of the solvent (50 mL) was distilled off and the residual suspension filtered. The solution was concentrated obtaining, a solid residue (170 mg) containing compound I [wherein $R_1 = \text{Ph}$, $R_2 = \text{H}$, $R_3 = \text{CH}(\text{COOH})\text{CH}_2\text{Ph}$, $R_4 = \text{H}$, $R_5 = \text{H}$, $R_6 = \text{COOH}$, $X = \text{O}$, $Z = \text{O}$, $Y = \text{O}$].

[0047] Crude compound I [wherein $R_1 = \text{Ph}$, $R_2 = \text{H}$, $R_3 = \text{CH}(\text{COOH})\text{CH}_2\text{Ph}$, $R_4 = \text{H}$, $R_5 = \text{H}$, $R_6 = \text{COOH}$, $X = \text{O}$, $Z = \text{O}$, $Y = \text{O}$] treated with solution of diazomethane in ether gave compound I [wherein $R_1 = \text{Ph}$, $R_2 = \text{H}$, $R_3 = \text{CH}(\text{COOMe})\text{CH}_2\text{Ph}$, $R_4 = \text{H}$, $R_5 = \text{H}$, $R_6 = \text{COOMe}$, $X = \text{O}$, $Z = \text{O}$, $Y = \text{O}$] identical with the product (major epimer) as described in example 8.

Scheme 1




Scheme 2



Claims

1. Heterobicyclic derivatives of general formula (I)



wherein:

R_1 , is chosen in the group consisting of C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkinyl, cycloalkyl, aryl, heterocycle, aryl C_{1-8} alkyl; heterocycle C_{1-8} alkyl; $RR'N-C_{1-8}$ alkyl, $RR'N$ -aryl, RO -aryl, $R(O)C$ -aryl, $RO(O)C$ -aryl, $RR'N(O)C$ -aryl, $(P)-W-NR$ -aryl, $(P)-W-O$ -aryl, $(P)-W-C(O)O$ -aryl, $(P)-W-O(O)C$ -aryl, $(P)-W-C(O)RN$ -aryl, $(P)-W-NR(O)C$ -aryl;

R_2 , is chosen in the group consisting of H, C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkinyl, cycloalkyl, aryl, aryl C_{1-8} alkyl; heterocycle C_{1-8} alkyl; amino C_{1-8} alkyl, aminoaryl, C_{1-8} alkyloxyaryl, hydroxyaryl, carboxyaryl, carboalkyloxyaryl, alkylcarbamoylearyl, -(side chain), -(side chain)- W -(P) or

R_1 and R_2 taken together are a C_{1-4} alkyl, C_{2-4} alkenyl, cycloalkyl, benzofused cycloalkyl, to form a bridge of 3, 4, 5, 6 terms;

R_3 , is chosen in the group consisting of H, C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkinyl, cycloalkyl, aryl, aryl C_{1-8} alkyl; heterocycle C_{1-8} alkyl; $RR'NC_{1-8}$ alkyl, $RR'N$ aryl, $RO-C_{1-8}$ alkyl,

$RO(O)C-C_{1-8}$ alkyl, $R(O)C-C_{1-8}$ alkyl, $RC(O)O-C_{1-8}$ alkyl, $RC(O)N(R)C_{1-8}$ alkyl RO -aryl, $RO(O)C$ -aryl, $R(O)C$ -aryl, $RC(O)O$ -aryl, $RC(O)N(R)$ aryl, $-CH$ (amino acid side-chain) CO_2R , $-CH$ (amino acid side-chain) $C(O)NR$, $-CH$ (amino acid side-chain) $C(O)O-W$ -(P), $-CH$ (amino acid side-chain) $C(O)N(R)-W$ -(P), $CH(CO_2R)$ -amino acid side-chain- W -(P), $CH(CONRR')$ -amino acid side-chain- W -(P), protecting group;

R_4 and R_5 , same or different, are chosen in the group consisting of H, C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkinyl, cycloalkyl, aryl, heterocycle, aryl C_{1-8} alkyl; heterocycle C_{1-8} alkyl;

R_6 is chosen in the group consisting of H, C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkinyl, cycloalkyl, aryl, aryl C_{1-8} alkyl, heterocycle, heterocycle C_{1-8} alkyl; $-C(O)R$, $-C(O)OR$, $-C(O)NRR'$, CH_2OR , CH_2NRR' , $-C(O)NH-CH$ (amino acid side-chain) $C(O)OR$, $-C(O)O-W$ -(P), $-C(O)N(R)-W$ -(P), $-CH_2O-W$ -(P), $-CH_2N(R)-W$ -(P);

R and R' , same or different, are chosen in the group consisting of: H, C_{1-8} alkyl,

C_{2-8} alkenyl, C_{2-8} alkinyl, cycloalkyl, aryl, heterocycle, aryl C_{1-8} alkyl; heterocycle C_{1-8} alkyl; a protecting group, $-C(O)CH$ (amino acid side-chain)- NHR , $-NH-CH$ (amino acid side-chain) $COOR$, $-CH$ (amino acid side-chain) $COOR$;

P is resin, both soluble or bound to a solid support;

W is as linker;

X is O, S, when a is a double bond, or X is H and a is single bond,

Y and Z , same or different, are O, S, SO, SO_2 , N-R, wherein R is as above defined;

the above said alkyl-, alkenyl-, alkinyl-, cycloalkyl-, aryl- and heterocycle-groups, being possibly substituted.

2. Heterobicycle derivatives according to Claim 1 wherein:

the resin P is a polymeric material soluble in the solvents commonly used in organic synthesis or bound to a solid support;

the solid support is a solid material (at room temperature) to which starting resin materials (reactive groups) may be bound;

W is a molecule capable of binding the resin P to the reagents and the products of formula (I);

Protecting group means any group capable of preventing the atom to which it is attached from participating in an undesired reaction or bonding, as commonly used in synthesis reactions.

Amino acid side-chain means the side chain moieties of the natural occurring L or D amino acids or the non naturally occurring amino acids; and the other substituents are as defined in Claim 1.

3. Heterobicycle derivatives according to Claim 2 wherein:

the resin is a polymeric material derivatised with a $-NH_2$ group or an hydroxyl group possibly bound to a solid support materials chosen among polyethylene and polystyrene compounds and related inert polymeric compounds;

protecting groups are those which prevent reaction or bonding of oxygen, nitrogen, carboxylic acids, thiols, alcohols, amines and the like;

the amino acid side-chain is the side chain of a naturally or non naturally occurring amino acid and the other substituents are as defined in Claim 1.

4. Heterobicycle derivatives according to Claim 3 wherein the non naturally occurring amino acids are chosen among, norleucine (Nle), norvaline (NVa), β -alanine, L or D α -phenyl glycine and the like and the other substituents are as described in Claim 1.

5. Heterobicycle derivatives according to Claim 4 represented by the following formulae:

Comp.	X	Z	Y	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆
1.	O	O	O	Ph	H	PhCH ₂	H	H	COOH
2.	O	O	O	4-HO-Ph	H	PhCH ₂	H	H	COOH
3.	O	O	O	4-O ₂ N-Ph	H	PhCH ₂	H	H	COOH
4.	O	O	O	4-H ₂ N-Ph	H	PhCH ₂	H	H	COOH
5.	O	O	O	4-MeO(O)C-Ph	H	PhCH ₂	H	H	COOH
6.	O	O	O	4-Me-Ph	H	PhCH ₂	H	H	COOH
7.	O	O	O	4-MeO-Ph	H	PhCH ₂	H	H	COOH
8.	O	O	O	4-Cl-Ph	H	PhCH ₂	H	H	COOH
9.	O	O	O	4-Br-Ph	H	PhCH ₂	H	H	COOH
10.	O	O	O	2-HO-Ph	H	PhCH ₂	H	H	COOH
11.	O	O	O	2-O ₂ N-Ph	H	PhCH ₂	H	H	COOH
12.	O	O	O	2-H ₂ N-Ph	H	PhCH ₂	H	H	COOH
13.	O	O	O	2-MeO(O)C-Ph	H	PhCH ₂	H	H	COOH
14.	O	O	O	2-Me-Ph	H	PhCH ₂	H	H	COOH
15.	O	O	O	2-MeO-Ph	H	PhCH ₂	H	H	COOH
16.	O	O	O	2-Cl-Ph	H	PhCH ₂	H	H	COOH
17.	O	O	O	2-Br-Ph	H	PhCH ₂	H	H	COOH
18.	O	O	O	2-Nafthyl	H	PhCH ₂	H	H	COOH
19.	O	O	O	2-thienyl	H	PhCH ₂	H	H	COOH
20.	O	O	O	4-biphenyl	H	PhCH ₂	H	H	COOH
21.	O	O	O	Ph	H	Me	H	H	COOH
22.	O	O	O	Ph	H	CH ₃ (CH ₂) ₂	H	H	COOH
23.	O	O	O	Ph	H	cyclohexyl	H	H	COOH
24.	O	O	O	Ph	H	allyl	H	H	COOH
25.	O	O	O	Ph	H	Ph	H	H	COOH
26.	O	O	O	Ph	H	4-HO-Ph	H	H	COOH
27.	O	O	O	Ph	H	4-O ₂ N-Ph	H	H	COOH
28.	O	O	O	Ph	H	4-MeO ₂ C-Ph	H	H	COOH
29.	O	O	O	Ph	H	4-Me-Ph	H	H	COOH
30.	O	O	O	Ph	H	4-MeO-Ph	H	H	COOH
31.	O	O	O	Ph	H	4-Cl-Ph	H	H	COOH
32.	O	O	O	Ph	H	4-Br-Ph	H	H	COOH
33.	O	O	O	Ph	H	2-HO-Ph	H	H	COOH
34.	O	O	O	Ph	H	2-O ₂ N-Ph	H	H	COOH
35.	O	O	O	Ph	H	2-MeO ₂ C-Ph	H	H	COOH
36.	O	O	O	Ph	H	2-Me-Ph	H	H	COOH
37.	O	O	O	Ph	H	2-MeO-Ph	H	H	COOH

(continued)

Comp.	X	Z	Y	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆
38.	O	O	O	Ph	H	2-Cl-Ph	H	H	COOH
39.	O	O	O	Ph	H	2-Br-Ph	H	H	COOH
40.	O	O	O	Ph	H	2-Naphthyl	H	H	COOH
41.	O	O	O	Ph	H	2-thienyl	H	H	COOH
42.	O	O	O	Ph	H	4-biphenyl	H	H	COOH
43.	O	O	O	Ph	H	4-MeO ₂ C-PhCH ₂	H	H	COOH
44.	O	O	O	Ph	H	4-Me-PhCH ₂	H	H	COOH
45.	O	O	O	Ph	H	4-MeOPhCH ₂	H	H	COOH
46.	O	O	O	Ph	H	4-Cl-PhCH ₂	H	H	COOH
47.	O	O	O	Ph	H	4-Br-PhCH ₂	H	H	COOH
48.	O	O	O	Ph	H	2-HO-PhCH ₂	H	H	COOH
49.	O	O	O	Ph	H	2-O ₂ N-PhCH ₂	H	H	COOH
50.	O	O	O	Ph	H	2-MeO ₂ C-PhCH ₂	H	H	COOH
51.	O	O	O	Ph	H	2-Me-PhCH ₂	H	H	COOH
52.	O	O	O	Ph	H	2-MeO-PhCH ₂	H	H	COOH
53.	O	O	O	Ph	H	2-Cl-PhCH ₂	H	H	COOH
54.	O	O	O	Ph	H	2-Br-PhCH ₂	H	H	COOH
55.	O	O	O	4-HO-Ph	H	4-HO-PhCH ₂	H	H	COOH
56.	O	O	O	4-HO-Ph	H	4-O ₂ N-PhCH ₂	H	H	COOH
57.	O	O	O	4-HO-Ph	H	4-MeO ₂ C-PhCH ₂	H	H	COOH
58.	O	O	O	4-HO-Ph	H	4-Me-PhCH ₂	H	H	COOH
59.	O	O	O	4-HO-Ph	H	4-MeOPhCH ₂	H	H	COOH
60.	O	O	O	4-HO-Ph	H	4-Cl-PhCH ₂	H	H	COOH
61.	O	O	O	4-HO-Ph	H	4-Br-PhCH ₂	H	H	COOH
62.	O	O	O	4-HO-Ph	H	2-HO-PhCH ₂	H	H	COOH
63.	O	O	O	4-HO-Ph	H	2-O ₂ N-PhCH ₂	H	H	COOH
64.	O	O	O	4-HO-Ph	H	2-MeO ₂ C-PhCH ₂	H	H	COOH
65.	O	O	O	4-HO-Ph	H	2-Me-PhCH ₂	H	H	COOH
66.	O	O	O	4-HO-Ph	H	2-MeO-PhCH ₂	H	H	COOH
67.	O	O	O	4-HO-Ph	H	2-Cl-PhCH ₂	H	H	COOH
68.	O	O	O	4-HO-Ph	H	2-Br-PhCH ₂	H	H	COOH
69.	O	O	O	4-HO-Ph	H	Me	H	H	COOH
70.	O	O	O	4-HO-Ph	H	CH ₃ (CH ₂) ₂	H	H	COOH
71.	O	O	O	4-HO-Ph	H	cyclohexyl	H	H	COOH
72.	O	O	O	4-HO-Ph	H	allyl	H	H	COOH
73.	O	O	O	Ph	H	HO ₂ C-CH ₂	H	H	COOH
74.	O	O	O	Ph	H	Bn(HO ₂ C)CH	H	H	COOH
75.	O	O	O	Ph	H	HOCH ₂ (HO ₂ C)CH	H	H	COOH
76.	O	O	O	Ph	H	CH ₃ (HO)CH(HO ₂ C)CH	H	H	COOH
77.	O	O	O	Ph	H	MeS(CH ₂) ₂ (HO ₂ C)CH	H	H	COOH
78.	O	O	O	Ph	H	H ₂ N(CH ₂) ₃ (HO ₂ C)CH	H	H	COOH
79.	O	O	O	Ph	H	HO ₂ CCH ₂ (HO ₂ C)CH	H	H	COOH
80.	O	O	O	Ph	H	imidazole-CH ₂ (HO ₂ C)CH	H	H	COOH
81.	O	O	O	Ph	H	indole-CH ₂ (HO ₂ C)CH	H	H	COOH
82.	O	O	O	4-HO-Ph	H	HO ₂ C-CH ₂	H	H	COOH
83.	O	O	O	4-HO-Ph	H	Me(HO ₂ C)CH	H	H	COOH
84.	O	O	O	4-HO-Ph	H	(CH ₃) ₂ CH(HO ₂ C)CH	H	H	COOH
85.	O	O	O	4-HO-Ph	H	Bn(HO ₂ C)CH	H	H	COOH
86.	O	O	O	4-HO-Ph	H	HOCH ₂ (HO ₂ C)CH	H	H	COOH

(continued)

Comp.	X	Z	Y	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆
87.	O	O	O	4-HO-Ph	H	CH ₃ (HO)CH(HO ₂ C)CH	H	H	COOH
88.	O	O	O	4-HO-Ph	H	MeS(CH ₂) ₂ (HO ₂ C)CH	H	H	COOH
89.	O	O	O	4-HO-Ph	H	H ₂ N(CH ₂) ₃ (HO ₂ C)CH	H	H	COOH
90.	O	O	O	4-HO-Ph	H	HO ₂ CCH ₂ (HO ₂ C)CH	H	H	COOH
91.	O	O	O	4-HO-Ph	H	imidazole-CH ₂ (HO ₂ C)CH	H	H	COOH
92.	O	O	O	4-HO-Ph	H	indole-CH ₂ (HO ₂ C)CH	H	H	COOH
93.	O	O	O	Ph	Me	PhCH ₂	H	H	COOH
94.	O	O	O	4-HO-Ph	Me	PhCH ₂	H	H	COOH
95.	O	O	O	Ph	Bn	PhCH ₂	H	H	COOH
96.	O	O	O	4-HO-Ph	Bn	PhCH ₂	H	H	COOH
97.	O	O	O	Ph	Me	HO ₂ C-CH ₂	H	H	COOH
98.	O	O	O	4-HO-Ph	Me	HO ₂ C-CH ₂	H	H	COOH
99.	O	O	O	Ph	Bn	HO ₂ C-CH ₂	H	H	COOH
100.	O	O	O	4-HO-Ph	Bn	HO ₂ C-CH ₂	H	H	COOH
101.	O	O	O	Ph	Me	Bn(HO ₂ C)CH	H	H	COOH
102.	O	O	O	4-HO-Ph	Me	Bn(HO ₂ C)CH	H	H	COOH
103.	O	HN	O	Ph	H	PhCH ₂	H	H	CH ₃
104.	O	HN	O	Ph	Me	PhCH ₂	H	H	CH ₃
105.	O	HN	O	Ph	Bn	PhCH ₂	H	H	CH ₃
106.	O	HN	O	4-OH-Ph	H	PhCH ₂	H	H	CH ₃
107.	O	HN	O	4-OH-Ph	Me	PhCH ₂	H	H	CH ₃
108.	O	HN	O	4-OH-Ph	Bn	PhCH ₂	H	H	CH ₃
109.	O	HN	O	Ph	H	Ph	H	H	CH ₃
110.	O	HN	O	Ph	Me	Ph	H	H	CH ₃
111.	O	HN	O	Ph	Bn	Ph	H	H	CH ₃
112.	O	HN	O	4-OH-Ph	H	Ph	H	H	CH ₃
113.	O	HN	O	4-OH-Ph	Me	Ph	H	H	CH ₃
114.	O	HN	O	4-OH-Ph	Bn	Ph	H	H	CH ₃
115.	O	HN	O	Ph	H	CH ₃ -Ph	H	H	CH ₃
116.	O	HN	O	Ph	Me	CH ₃ -Ph	H	H	CH ₃
117.	O	HN	O	Ph	Bn	CH ₃ -Ph	H	H	CH ₃
118.	O	HN	O	4-OH-Ph	H	CH ₃ -Ph	H	H	CH ₃
119.	O	HN	O	4-OH-Ph	Me	CH ₃ -Ph	H	H	CH ₃
120.	O	HN	O	4-OH-Ph	Bn	CH ₃ -Ph	H	H	CH ₃
121.	O	HN	O	Ph	H	4-MeO-PhCH ₂	H	H	CH ₃
122.	O	HN	O	Ph	Me	4-MeO-PhCH ₂	H	H	CH ₃
123.	O	HN	O	Ph	Bn	4-MeO-PhCH ₂	H	H	CH ₃
124.	O	HN	O	4-OH-Ph	H	4-MeO-PhCH ₂	H	H	CH ₃
125.	O	HN	O	4-OH-Ph	Me	4-MeO-PhCH ₂	H	H	CH ₃
126.	O	HN	O	4-OH-Ph	Bn	4-MeO-PhCH ₂	H	H	CH ₃
127.	O	HN	O	Ph	H	CH ₃ -PhCH ₂	H	H	CH ₃
128.	O	HN	O	Ph	Me	CH ₃ -PhCH ₂	H	H	CH ₃
129.	O	HN	O	Ph	Bn	CH ₃ -PhCH ₂	H	H	CH ₃
130.	O	HN	O	4-OH-Ph	H	CH ₃ -PhCH ₂	H	H	CH ₃
131.	O	HN	O	4-OH-Ph	Me	CH ₃ -PhCH ₂	H	H	CH ₃
132.	O	HN	O	4-OH-Ph	Bn	CH ₃ -PhCH ₂	H	H	CH ₃
133.	O	HN	O	Ph	H	Me	H	H	CH ₃
134.	O	HN	O	Ph	H	CH ₃ (CH ₂) ₂	H	H	CH ₃
135.	O	HN	O	Ph	H	cyclohexyl	H	H	CH ₃

(continued)

Comp.	X	Z	Y	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆
136.	O	HN	O	Ph	H	allyl	H	H	CH ₃
137.	O	HN	O	4-OH-Ph	H	Me	H	H	CH ₃
138.	O	HN	O	4-OH-Ph	H	CH ₃ (CH ₂) ₂	H	H	CH ₃
139.	O	HN	O	4-OH-Ph	H	cyclohexyl	H	H	CH ₃
140.	O	HN	O	4-OH-Ph	H	allyl	H	H	CH ₃
141.	O	HN	O	Ph	H	HO ₂ C-CH ₂	H	H	CH ₃
142.	O	HN	O	Ph	Me	HO ₂ C-CH ₂	H	H	CH ₃
143.	O	HN	O	Ph	Bn	HO ₂ C-CH ₂	H	H	CH ₃
144.	O	HN	O	4-OH-Ph	H	HO ₂ C-CH ₂	H	H	CH ₃
145.	O	HN	O	4-OH-Ph	Me	HO ₂ C-CH ₂	H	H	CH ₃
146.	O	HN	O	4-OH-Ph	Bn	HO ₂ C-CH ₂	H	H	CH ₃
147.	O	HN	O	Ph	H	Bn(HO ₂ C)CH	H	H	CH ₃
148.	O	HN	O	Ph	Me	Bn(HO ₂ C)CH	H	H	CH ₃
149.	O	HN	O	Ph	Bn	Bn(HO ₂ C)CH	H	H	CH ₃
150.	O	HN	O	4-OH-Ph	H	Bn(HO ₂ C)CH	H	H	CH ₃
151.	O	HN	O	4-OH-Ph	Me	Bn(HO ₂ C)CH	H	H	CH ₃
152.	O	HN	O	4-OH-Ph	Bn	Bn(HO ₂ C)CH	H	H	CH ₃
153.	H	O	O	Ph	H	PhCH ₂	H	H	COOH
154.	H	O	O	Ph	Me	PhCH ₂	H	H	COOH
155.	H	O	O	Ph	Bn	PhCH ₂	H	H	COOH
156.	H	O	O	4-HO-Ph	H	PhCH ₂	H	H	COOH
157.	H	O	O	4-HO-Ph	Me	PhCH ₂	H	H	COOH
158.	H	O	O	4-HO-Ph	Bn	PhCH ₂	H	H	COOH
159.	H	O	O	Ph	H	HO ₂ C-CH ₂	H	H	COOH
160.	H	O	O	Ph	Me	HO ₂ C-CH ₂	H	H	COOH
161.	H	O	O	Ph	Bn	HO ₂ C-CH ₂	H	H	COOH
162.	H	O	O	4-HO-Ph	H	HO ₂ C-CH ₂	H	H	COOH
163.	H	O	O	4-HO-Ph	Me	HO ₂ C-CH ₂	H	H	COOH
164.	H	O	O	4-HO-Ph	Bn	HO ₂ C-CH ₂	H	H	COOH
165.	H	O	O	Ph	H	Bn(HO ₂ C)CH	H	H	COOH
166.	H	O	O	Ph	Me	Bn(HO ₂ C)CH	H	H	COOH
167.	H	O	O	Ph	Bn	Bn(HO ₂ C)CH	H	H	COOH
168.	H	O	O	4-HO-Ph	H	Bn(HO ₂ C)CH	H	H	COOH
169.	H	O	O	4-HO-Ph	Me	Bn(HO ₂ C)CH	H	H	COOH
170.	H	O	O	4-HO-Ph	Bn	Bn(HO ₂ C)CH	H	H	COOH
171.	H	HN	O	Ph	H	PhCH ₂	H	H	CH ₃
172.	H	HN	O	Ph	H	4-MeO-PhCH ₂	H	H	CH ₃
173.	H	HN	O	Ph	Me	PhCH ₂	H	H	CH ₃
174.	H	HN	O	Ph	Bn	PhCH ₂	H	H	CH ₃
175.	H	HN	O	4-OH-Ph	H	PhCH ₂	H	H	CH ₃
176.	H	HN	O	4-OH-Ph	Me	PhCH ₂	H	H	CH ₃
177.	H	HN	O	4-OH-Ph	Bn	PhCH ₂	H	H	CH ₃
178.	H	HN	O	Ph	H	HO ₂ C-CH ₂	H	H	CH ₃
179.	H	HN	O	Ph	Me	HO ₂ C-CH ₂	H	H	CH ₃
180.	H	HN	O	Ph	Bn	HO ₂ C-CH ₂	H	H	CH ₃
181.	H	HN	O	4-OH-Ph	H	HO ₂ C-CH ₂	H	H	CH ₃
182.	H	HN	O	4-OH-Ph	Me	HO ₂ C-CH ₂	H	H	CH ₃
183.	H	HN	O	4-OH-Ph	Bn	HO ₂ C-CH ₂	H	H	CH ₃
184.	H	HN	O	Ph	H	Bn(HO ₂ C)CH	H	H	CH ₃


(continued)

Comp.	X	Z	Y	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆
185.	H	HN	O	Ph	Me	Bn(HO ₂ C)CH	H	H	CH ₃
186.	H	HN	O	Ph	Bn	Bn(HO ₂ C)CH	H	H	CH ₃
187.	H	HN	O	4-OH-Ph	H	Bn(HO ₂ C)CH	H	H	CH ₃
188.	H	HN	O	4-OH-Ph	Me	Bn(HO ₂ C)CH	H	H	CH ₃
189.	H	HN	O	4-OH-Ph	Bn	Bn(HO ₂ C)CH	H	H	CH ₃
190.	H	HN	O	Ph	H	Ph	H	H	CH ₃
191.	H	HN	O	Ph	Me	Ph	H	H	CH ₃
192.	H	HN	O	Ph	Bn	Ph	H	H	CH ₃
193.	H	HN	O	4-OH-Ph	H	Ph	H	H	CH ₃
194.	H	HN	O	4-OH-Ph	Me	Ph	H	H	CH ₃
195.	H	HN	O	4-OH-Ph	Bn	Ph	H	H	CH ₃
196.	H	HN	O	Ph	H	CH ₃ -Ph	H	H	CH ₃
197.	H	HN	O	Ph	Me	CH ₃ -Ph	H	H	CH ₃
198.	H	HN	O	Ph	Bn	CH ₃ -Ph	H	H	CH ₃
199.	H	HN	O	4-OH-Ph	H	CH ₃ -Ph	H	H	CH ₃
200.	H	HN	O	4-OH-Ph	Me	CH ₃ -Ph	H	H	CH ₃
201.	H	HN	O	4-OH-Ph	Bn	CH ₃ -Ph	H	H	CH ₃
202.	H	HN	O	Ph	H	4-MeO-PhCH ₂	H	H	CH ₃
203.	H	HN	O	Ph	Me	4-MeO-PhCH ₂	H	H	CH ₃
204.	H	HN	O	Ph	Bn	4-MeO-PhCH ₂	H	H	CH ₃
205.	H	HN	O	4-OH-Ph	H	4-MeO-PhCH ₂	H	H	CH ₃
206.	H	HN	O	4-OH-Ph	Me	4-MeO-PhCH ₂	H	H	CH ₃
207.	H	HN	O	4-OH-Ph	Bn	4-MeO-PhCH ₂	H	H	CH ₃
208.	H	HN	O	Ph	H	CH ₃ -PhCH ₂	H	H	CH ₃
209.	H	HN	O	Ph	Me	CH ₃ -PhCH ₂	H	H	CH ₃
210.	H	HN	O	Ph	Bn	CH ₃ -PhCH ₂	H	H	CH ₃
211.	H	HN	O	4-OH-Ph	H	CH ₃ -PhCH ₂	H	H	CH ₃
212.	H	HN	O	4-OH-Ph	Me	CH ₃ -PhCH ₂	H	H	CH ₃
213.	H	HN	O	4-OH-Ph	Bn	CH ₃ -PhCH ₂	H	H	CH ₃
214.	H	O	O	Ph	H	PhCH ₂	H	H	CH ₂ OH
215.	H	O	O	Ph	H	4-MeOPhCH ₂	H	H	CH ₂ OH
216.	H	O	O	Ph	Me	PhCH ₂	H	H	CH ₂ OH
217.	H	O	O	Ph	Bn	PhCH ₂	H	H	CH ₂ OH
218.	H	O	O	4-HO-Ph	H	PhCH ₂	H	H	CH ₂ OH
219.	H	O	O	4-HO-Ph	Me	PhCH ₂	H	H	CH ₂ OH
220.	H	O	O	4-HO-Ph	Bn	PhCH ₂	H	H	CH ₂ OH
221.	H	O	O	Ph	H	HOCH ₂	H	H	CH ₂ OH
222.	H	O	O	Ph	Me	HOCH ₂	H	H	CH ₂ OH
223.	H	O	O	Ph	Bn	HOCH ₂	H	H	CH ₂ OH
224.	H	O	O	4-HO-Ph	H	HOCH ₂	H	H	CH ₂ OH
225.	H	O	O	4-HO-Ph	Me	HOCH ₂	H	H	CH ₂ OH
226.	H	O	O	4-HO-Ph	Bn	HOCH ₂	H	H	CH ₂ OH
227.	H	O	O	Ph	H	Bn(HOH ₂ C)CH	H	H	CH ₂ OH
228.	H	O	O	Ph	Me	Bn(HOH ₂ C)CH	H	H	CH ₂ OH
229.	H	O	O	Ph	Bn	Bn(HOH ₂ C)CH	H	H	CH ₂ OH
230.	H	O	O	4-HO-Ph	H	Bn(HOH ₂ C)CH	H	H	CH ₂ OH
231.	H	O	O	4-HO-Ph	Me	Bn(HOH ₂ C)CH	H	H	CH ₂ OH
232.	H	O	O	4-HO-Ph	Bn	Bn(HOH ₂ C)CH	H	H	CH ₂ OH
233.	H	HN	O	Ph	H	PhCH ₂	H	H	H

(continued)


Comp.	X	Z	Y	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆
234.	H	HN	O	Ph	H	4-MeO-PhCH ₂	H	H	H
235.	H	HN	O	Ph	Me	PhCH ₂	H	H	H
236.	H	HN	O	Ph	Bn	PhCH ₂	H	H	H
237.	H	HN	O	4-OH-Ph	H	PhCH ₂	H	H	H
238.	H	HN	O	4-OH-Ph	Me	PhCH ₂	H	H	H
239.	H	HN	O	4-OH-Ph	Bn	PhCH ₂	H	H	H
240.	H	HN	O	Ph	H	HOCH ₂	H	H	H
241.	H	HN	O	Ph	Me	HOCH ₂	H	H	H
242.	H	HN	O	Ph	Bn	HOCH ₂	H	H	H
243.	H	HN	O	4-OH-Ph	H	HOCH ₂	H	H	H
244.	H	HN	O	4-OH-Ph	Me	HOCH ₂	H	H	H
245.	H	HN	O	4-OH-Ph	Bn	HOCH ₂	H	H	H
246.	H	HN	O	Ph	H	Bn(HOH ₂ C)CH	H	H	H
247.	H	HN	O	Ph	Me	Bn(HOH ₂ C)CH	H	H	H
248.	H	HN	O	Ph	Bn	Bn(HOH ₂ C)CH	H	H	H
249.	H	HN	O	4-OH-Ph	H	Bn(HOH ₂ C)CH	H	H	H
250.	H	HN	O	4-OH-Ph	Me	Bn(HOH ₂ C)CH	H	H	H
251.	H	HN	S	Ph	H	PhCH ₂	H	H	H
252.	H	HN	S	Ph	H	4-MeO-PhCH ₂	H	H	H
253.	H	HN	S	Ph	Me	PhCH ₂	H	H	H
254.	H	HN	S	Ph	Bn	PhCH ₂	H	H	H
255.	H	HN	S	4-OH-Ph	H	PhCH ₂	H	H	H
256.	H	HN	S	4-OH-Ph	Me	PhCH ₂	H	H	H
257.	H	HN	S	4-OH-Ph	Bn	PhCH ₂	H	H	H
258.	H	HN	S	Ph	H	HOCH ₂	H	H	H
259.	H	HN	S	Ph	Me	HOCH ₂	H	H	H
260.	H	HN	S	Ph	Bn	HOCH ₂	H	H	H
261.	H	HN	S	4-OH-Ph	H	HOCH ₂	H	H	H
262.	H	HN	S	4-OH-Ph	Me	HOCH ₂	H	H	H
263.	H	HN	S	4-OH-Ph	Bn	HOCH ₂	H	H	H
264.	H	HN	S	Ph	H	Bn(HOH ₂ C)CH	H	H	H
265.	H	HN	S	Ph	Me	Bn(HOH ₂ C)CH	H	H	H
266.	H	HN	S	Ph	Bn	Bn(HOH ₂ C)CH	H	H	H
267.	H	HN	S	4-OH-Ph	H	Bn(HOH ₂ C)CH	H	H	H
268.	H	HN	S	4-OH-Ph	Me	Bn(HOH ₂ C)CH	H	H	H

6. Process for the preparation of compounds of formula (I) according to Claim 1 wherein a compound of formula (II)




II

wherein R₁, R₂, R₃, are as above defined
is reacted with a compound of formula (III)



wherein R_4 , R_5 , R_6 , Y and Z are as above defined and R_7 , R_8 represent H or suitable protecting groups, (Pg) which can be same or different, cyclic or acyclic, and which can be cleaved in acidic conditions, in order to give a compound of formula (IV)



wherein the substituents have the meaning as above, which is cyclised to a compound of formula (I) by action of an acid.

7. Process according to Claim 5 wherein the first step is performed in an aprotic polar solvent at a temperature comprised between 0 - 100°C for 1 - 24 hours.
8. Process according to Claim 6 wherein the reaction is performed in the presence of a coupling agent.
9. Process according to Claim 5 wherein the second step is performed in the presence of a strong acid at a temperature of 0°-150°C for 15min - 24 hours
10. Process according to Claim 8 wherein the acid is chosen in the group consisting of: sulphuric acid adsorbed on silica gel, p-toluen sulphonic acid, trifluoroacetic acid, trifluoromethanesulphonic acid.
11. Libraries consisting of compounds of formula (I) according to Claim 1.
12. Generation of combinatorial libraries according to Claim 10 in mixture synthesis, split and recombine synthesis and parallel synthesis either in manual or automated fashion.
13. Use of compounds of formula 1 for the preparation of new leads for therapeutical applications.
14. Use of libraries consisting of compounds of formula 1 for the preparation of new leads for therapeutical applications.



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 00 10 4135

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	BE 892 853 A (DELALANDE S.A.) 15 October 1982 (1982-10-15) * claims 1-4 *	1-4	C07D498/08 /(C07D498/08, 317:00, 265:00), (C07D498/08, 263:00,241:00)
X	J.-Q. WANG, W.-S. TIAN: J. CHEM. SOC. PERKIN TRANS. 1, no. 2, 1996, pages 209-212, XP002142445 * Compound of formula 12 * * page 210, right-hand column *	1-4	
D,X	A. GUARNA ET AL.: "Synthesis and Reactivity of Bicycles Derived from Tartaric Acid and alpha-Amino Acids: A Novel Class of Conformationally Constrained Dipeptide Isosteres Based upon Enantiopure 3-Aza-6,8-dioxabicyclo[3.2.1]octane-7-carboxylic Acid" J. ORG. CHEM., vol. 64, no. 20, 1999, pages 7347-7364, XP002142446 * table 1 *	1-13	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			C07D
Place of search MUNICH		Date of completion of the search 13 July 2000	Examiner Herz, C
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03/82 (P04C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 10 4135

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

13-07-2000

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
BE 892853 A	15-10-1982	FR 2504141 A	22-10-1982
		AU 8284582 A	28-10-1982
		DE 3214570 A	30-12-1982
		ES 512108 D	01-07-1983
		ES 8307253 A	16-10-1983
		GB 2096998 A, B	27-10-1982
		GR 75910 A	02-08-1984
		IT 1190782 B	24-02-1988
		JP 57188593 A	19-11-1982
		LU 84100 A	13-09-1982
		NL 8201642 A	16-11-1982
		SE 8202364 A	22-10-1982
		US 4463004 A	31-07-1984
		ZA 8202639 A	30-03-1983

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82